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ABSTRACT
Macromolecular complexes of cystic fibrosis transmembrane conductance
regulator (CFTR) comprise of network of proteins that can regulate cAMP-/cGMPactivated CFTR chloride channel function. We report the physical and functional
coupling of CFTR with nitric oxide (NO) producing enzyme-inducible nitric oxide
synthase (iNOS) at the apical plasma membrane in inflammatory bowel disease (IBD).
The complex formation requires the scaffolding protein Na+/H+ exchanger regulatory
factor 2 (NHERF2). We demonstrate that iNOS is overexpressed at or near the apical
plasma membrane of gut epithelial cells in IBD and, through the stimulation of the NOcGMP pathway, generates compartmentalized cGMP underneath the plasma membrane.
This action triggers the hyperactivation of CFTR chloride channels and causes secretory
diarrhea phenotype in IBD. Inhibition of CFTR and iNOS activity attenuates diarrhea in
dextran sodium sulfate (DSS) induced colitis. Dissolution of the macromolecular
complex in Nherf2 -/- mice renders them resistant to CFTR-mediated secretory diarrhea in
murine colitis models compared to Nherf2+/+. Our findings have important therapeutic
implications in IBD and other forms of gastrointestinal inflammations.
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CHAPTER 1.

COMPARTMENTALIZED CYCLIC NUCLEOTIDE
SIGNALING
Introduction

Cyclic nucleotides are the cellular messengers that relay environmental cues to
mobilize cellular responses. Important cyclic nucleotides inside the cell are cyclic
adenosine-3′,5′-monophosphate (cAMP) and cyclic guanosine-3′,5′-monophosphate
(cGMP) (1). These cellular messengers are now known to be involved in various cellular
responses to hormones and other types of stimuli and thereby, control diverse functions
(e.g., metabolism, cell proliferation, differentiation, migration and fluid secretion) (2). It
was first noticed by Bruxton and Brunton in 1980s that there is differentiation of cAMPdependent signaling processes in the cardiac myocytes (2-4). This concept came to be
formulated as compartmentalized signaling. At the molecular level, compartmentalized
cellular signaling would mean local sinks of cellular messengers capable of regulating
signaling events in a nodal manner inside the cell. A signaling process gets
compartmentalized when there is a generation of cyclic-nucleotides in the vicinity of their
effectors and the signal termination mechanisms are set in place to prevent the spatial
spread of the signaling. The receptors include protein kinases, kinase anchoring proteins,
guanine-nucleotide exchange factors and cyclic-nucleotide-gated channels (1).
Termination of the signaling process usually involves cyclic-nucleotide catabolizing
enzymes phosphodiesterases (PDEs) and in some cases, recently characterized cyclicnucleotide efflux transporters (2, 5). The typical advantage of the process of
compartmentalization is the spatiotemporal regulation of cyclic-nucleotide responsive
proteins in specialized microdomains allowing high velocity and specificity of the
responses. Apparently, compartmentalized signaling came into existence as an
evolutionary response to selection pressure as eukaryotic cells needed to respond rapidly
to the changing conditions and segregate simultaneously running signaling processes.
Compartmentalization of cAMP Signaling
Adenylyl cyclases and G protein coupled receptors initiate cAMP compartments
Generation of cAMP from ATP is dependent upon G-protein-coupled-receptor
(GPCR)-mediated stimulation of adenylyl cyclases (ACs) (3, 6). It has been observed that
certain membrane-bound AC isoforms can be selectively delivered to membrane rafts
(rafts are dynamic cholesterol and sphingolipids rich structures of plasma membrane that
play an important role in segregating signaling cascades at the membrane) where they
exhibit exquisite sensitivity for local sub-micromolar Ca2+ gradients (7). The soluble ACs
also exhibit compartmentalized distribution in close proximity with cAMP-responsive
proteins and have been found to closely communicate with localized bicarbonate
gradients (8). There are also reports on AC6 communicating with GPCRs β1/ β2Adrenergic receptors (ARs) in caveolin-rich domains of plasma membrane with the
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coupling efficiency varying as a function of external stimulus (9). The selective patching
of AC-GPCR signaling with an inherent role of heterogeneous physical barriers and with
the contribution of cytoskeletal elements, provides the first level of cAMPcompartmentalization.
Phosphodiesterases and A-kinase anchoring proteins
In view of high diffusion rates of cAMP (~220 μ meters s−1), it is of utmost
interest to know how cAMP mediated responses remain highly localized and specific (2,
10). There are mechanisms to annul cAMP generated inside the cell and in fact, the
cAMP hydrolysis has been estimated to be occurring faster than the cAMP synthesis (11).
PDEs constitute the major force of catabolizing cyclic nucleotides. PDEs break the
phosphodiester bond in cAMP and cGMP resulting in the formation of adenosine-5monophosphate (AMP) and guanosine-5-monophosphate (GMP), respectively. There are
eleven mammalian PDE gene families, three cAMP-specific (PDE4, PDE7, and PDE8),
three cGMP-specific (PDE5, PDE6, and PDE9), and five exhibit dual-specificities
(PDE1, PDE2, PDE3, PDE10, and PDE11) (2). The diversity and specificities of PDEregulated signaling are derived from the variability of different isoforms in tissue-type
expression, subcellular localization, and specific associations with adaptor and effector
proteins (12). FRET-based sensors which fundamentally comprise of genetically
modified cAMP-effectors such as EPAC and PKA subunits are immensely valuable for
studying PDE-mediated compartmentalized signaling (13). Based on studies using these
cyclic nucleotide sensors, it has been shown that pharmacological inhibition of PDEs
does not alter the global levels of cyclic messengers but rather their sub-cellular
distribution. It is now accepted that concerted actions of ACs and PDEs can create
localized gradients of cAMP (3). This concept gets more sophisticated with an incurred
process of GPCR desensitization because of the major regulatory role of PDE. For
example, PDE4D5 can dampen β2-AR signaling upon β-arrestin mediated recruitment of
the enzyme to the phosphorylated β2-AR. β-arrestins uncouple β2-AR from Gs, essential
for β2-AR desensititzation (3). PDE4D5- β-arrestins complex will apparently accelerate
the process of desensititzation where uncoupling of β2-AR from Gs will occur
concurrently with cAMP degradation by PDE4D5 and prepare β2-AR for another round
of agonist-induced activation (3). PDE3 inhibitor cilostazol can potentiate cystic fibrosis
transmembrane conductance regulator (CFTR) Cl- channel function as PDE3A directly
interacts with CFTR at the apical surface in epithelial cells (4). Notably, PDE3 inhibition
generates compartmentalized cAMP at the plasma membrane causing highly localized
activation of CFTR Cl- channel function.
It has been found that PDEs can localize to specific subcellular domains via
binding to A-Kinase anchoring protein (AKAP) (14). AKAP recognizes the N-terminal of
regulatory subunit II of cAMP-activated protein kinase A (PKA) and tethers PKA at
distinct subcellular locations allowing spatiotemporal regulation of PKA substrates (3).
Certain PDEs, AKAPs, kinases and phosphatases have analogous targeting mechanisms
(specific for protein-protein or protein-lipid interactions) (3). PDE4D3 and PKA run a
concerted negative feedback loop for cAMP signaling onto a muscle specific AKAP
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(mAKAP) maintained signaling module that controls the output of ventricular
hypertrophy (15). Neuronal anchoring protein AKAP79 was found to bind to the
phosphatase calcineurin and diminish the phosphorylation of PKA substrates and later, to
protein kinase C (PKC) which can act on an overlapping but distinct set of substrates (16,
17). Also, AKAPs exhibit discrete subcellular targeting where they can nucleate distinct
protein complexes. The plasma membrane-associated Yotiao, a smallest splice variant of
the AKAP9 family tethers PKA, protein phosphatase 1, PDE4D3, the NR1 subunit of the
NMDA receptor, IP3 receptor, and the K+ channel subunit KCNQ1 to control IKs currents
in the heart (18). Ezrin is an AKAP enriched in microvilli on the apical side of polarized
epithelial cells which regulates the PKA-mediated inhibition of Na+/H+ exchanger 3
(NHE3) and activation of CFTR via Ezrin-binding protein Na+/H+ exchange regulatory
factor 1 (NHERF1) (19-22). Ezrin also binds F-actin which determines the stability of
CFTR at the plasma membrane (23). Thus, AKAPs assemble large multi-protein
complexes which act as nodes of enzymatic and regulatory activities.
Multiple drug resistance proteins: cyclic nucleotide efflux transporters
Davoren and Sutherland observed that hormonal stimulation of the cells would
alter not only the intracellular but also the extracellular cAMP levels (2). To explain this
observation, it was rationalized that cells use an unidentified cyclic nucleotide export
system. Later, a member of the ABC transporter family termed as multidrug resistance
protein 4 (MRP4; also known as ABCC4), was identified to efflux cAMP as well as
cGMP (24, 25). The affinity constant of MRP4 for cGMP (10μM) is lower than for
cAMP (45μM) (25).
MRP4 is ubiquitously expressed in many cell types polarized and non-polarized
and in the former type lines both apical and basolateral membranes of the epithelial cells
(2). Interestingly, MRP4 inhibition alone could not substantially change the total cyclic
nucleotide levels, which clearly signifies the role of MRP4 in compartmentalized
signaling. Li et al. reported an important role of apical MRP4 in regulating CFTR
function in a highly compartmentalized manner in the gut epithelial cells (5). Recent
studies reported that MRP4 can be anchored by caveolins in the plasma membrane where
it participates in highly segregated signaling modules (26). We recently demonstrated that
MRP4 can control distinct PKA activities at the leading vs. lagging edge of a migrating
fibroblast to regulate the migration process (27). Also, regulation of migration gets
biphasic as MRP4 segregates between cAMP and cGMP-mediated signaling and directs
different migration outputs (27). Other additional ABC transporters have been identified
to export cyclic nucleotides which include MRP5, ABCG2 and MRP8 (2). Therefore,
cyclic nucleotide extrusion from the cell by certain ABC transporters represents an
additional mechanism to attenuate the signaling process and also, there have been
observations fostering the fact that these two mechanisms may act compensatory or in
concert (2).
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Compartmentalization of cGMP Signaling
Studies related to elucidating cGMP signaling are less well-understood compared
to the cAMP pathways. Robert F. Furchgott, Louis J. Ignarro and Ferid Murad won 1998
Nobel Prize in Physiology or Medicine for studying the significance of nitric oxide (NO)cGMP pathway in cardiovascular health which underscores the importance of cGMP
pathways in the living systems. cGMP plays role in several important biological
functions such as vascular tone regulation, epithelial electrolyte transport, migration,
neurotransmission and immunomodulation (28). cGMP is synthesized by NO-responsive
soluble (sGC) or membrane-associated particulate (pGC) form of guanylyl cyclases.
Seven isoforms of pGCs have been identified which include natriuretic peptide receptors
GC-A and GC-B, GC-C which are responsive to bacterial heat-stable enterotoxins,
guanylin, and uroguanylin and orphan receptors GC-D to G (28). The process of cGMP
compartmentation is vaguely known compared to cAMP however; the same question can
be applied asking how different extracellular cues fundamentally working through a
common intracellular messenger can produce varied biological responses. It is likely, that
similar mechanisms and components to enable compartmentalization of cGMP signaling
would exist as are known for cAMP. Recent studies report that GC-C communicates with
intracellular p21-activated kinase via Rac GTPase to regulate cell migration and actin
cytoskeletal restructuring (29). The basis of this process would be asymmetric and
segregated signaling that regulates the directed cell migration (27, 29). cGMP-dependent
protein kinases (PKGs) are the most important effectors of cGMP response. G-kinase
anchoring proteins (GKAPs) are the proteins required for the dissemination of PKGsignaling. However, the field is very new and limited information is available.
Scaffolding protein NHERF2 has been shown to function as (GKAP) to mediate cGMPdependent regulation of NHE3 allowing the compartmentalized regulation of the protein
(30). Since cGMP can increase CFTR chloride activity and it is known that CFTR can
bind to NHERF2, NHERF2 can regulate cGMP-dependent activation of CFTR which
would also likely to be occurring in membrane restricted compartments. Few other
GKAPs include vimentin, guanylate cyclase A, troponin T, myosin light chain kinase,
testicular golgi protein GKAP42 (30). Neutralizing components of cGMP signaling
importantly include cGMP catabolizing PDEs: PDE5, PDE6, and PDE9. Five PDEs
(PDE1, PDE2, PDE3, PDE10, and PDE11) exhibit dual specificities for cAMP and
cGMP. These dual-specificity PDEs (in particular reported to be PDE2 and PDE3) play
critical roles in cross-talks between cGMP and cAMP-dependent signaling (31, 32). An
important role of spatiotemporal regulation of functional NO-cGMP signaling system has
been described in cell fate decisions and lineage determination during the early
differentiation process of embryonic stem cells (33).
In this study we determine how compartmental cGMP becomes the
pathophysiological basis of CFTR-dependent diarrhea in inflammatory bowel disorders
(IBD). We elucidate formation of a CFTR-containing macromolecular complex as the
molecular basis of diarrheal phenotype of IBD.
In conclusion, the concept of compartmentalized signaling as of today is
astonishingly advanced and intricate. This is primarily attributed to appreciating how the
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process of compartmentalized signaling is fundamentally relevant to cellular behavior in
health and disease and the availability of scientific tools which allow monitoring the
process very efficiently.
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CHAPTER 2. MACROMOLECULAR COMPLEX OF CFTR AND
INDUCIBLE-NOS AT THE PLASMA MEMBRANE IN INFLAMMATORY
BOWEL DISEASES
Cystic Fibrosis Transmembrane Conductance Regulator
Compartmentalized signaling has been shown to extensively regulate the activity
of Cl channel CFTR (or ABCC7) at the plasma membrane (34, 35). CFTR is a 1480
amino-acid long membrane-bound protein belonging to the ATP-binding cassette
transporter (ABC) superfamily which consumes energy from ATP hydrolysis to transport
a wide-variety of substrates (34, 35). CFTR consists of two homologous halves, each
composed of a hydrophobic membrane-spanning domain (MSD) containing six
transmembrane helices and a cytosolic nucleotide binding domain (NBD). The two NBDs
are linked by a cytoplasmic regulatory domain (R domain) which contains multiple
consensus phosphorylation sites for several kinases. The phosphorylation state of CFTR
determines the channel open probability (P). The structure of CFTR is shown in Figure
2-1.
-

Interestingly, it was reported that the amino (N) terminus cytoplasmic region of
CFTR is involved in a direct interaction with the R domain via a conserved set of
residues which will determine the steady-state activity of CFTR (36). CFTR is an
epithelial cell protein present on the apical membranes in the gut, lung airways, sweat
gland, pancreas and urogenital tract that regulates fluid balance across the epithelia lining
these organs (37).
Macromolecular Complexes of CFTR
CFTR is a cAMP-/cGMP-activated Cl- / HCO3- transporter (38, 39). The most
interesting aspect of CFTR regulation is the formation of multi-protein complexes via its
N and carboxyl (C) terminals. A direct interaction at the N terminus of CFTR with the
regulatory SNARE ( soluble N-ethylmaleimide-sensitive-factor attachment protein
receptor) protein Syntaxin 1A negatively modulates CFTR function and is subject to
competitive inhibition by Syntaxin 1A–binding protein Munc 18 (40). Such interactions
will be critical to regulate the dynamics of CFTR channel activity according to a
physiological cue. Macromolecular complexes of CFTR involving regulators and
effectors of cAMP would lead to highly compartmentalized regulation of CFTR within
cAMP microdomains at the plasma membrane. The cAMP-elevating ligand adenosine
(ADO; 1-20 μM) which acts through adenosine receptor subtypes belonging to GPCR
family can also stimulate CFTR-mediated Cl- currents in a compartmentalized manner at
the apical cell membrane of polarized epithelial cells (41). In cell-attached single-channel
recordings of CFTR, it was observed that the AC stimulating agent forskolin (Fsk), or
cell-permeant cpt-cAMP always elicited a global cAMP response and activated CFTR
irrespective of whether these reagents were applied in the pipette or in the bath (42). In
contrast sub-micromolar concentrations of ADO evoked a localized activation of CFTR,
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Figure 2-1.

Structure of CFTR protein

CFTR protein topology showing various domains of the CFTR protein: two membrane
spanning domains (colored in orange), two nucleotide binding domains (colored in red)
and a regulatory domain (colored in light blue).
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as ADO when added to the bath failed to activate CFTR function (42).
PDZ-scaffolds
Most of the macromolecular formations of CFTR at the C terminus are mediated
by a class of scaffolding proteins termed as PSD-95/DLG-5/ZO-1 (PDZ)-domain proteins
(34, 37). PDZ domains are named after the first three identified PDZ-domain containing
proteins which include postsynaptic density protein-95 (PSD-95), the drosophila
junctional protein Disc-large (DLG), and the epithelial tight junction protein zonula
occludens (ZO)-1. PDZ modules are small approximately 90 amino-acids long and
recognize four to six residues of the target proteins. PDZ domains constitute among the
most commonly expressed domains in an eukaryotic genome and have been estimated to
number greater than 400 in human (43). With such an abundance and diversity, PDZproteins apparently regulate many signal transduction events inside the cell (44). The
primary role of PDZ proteins is to function as scaffolds to assemble large protein
complexes that facilitate coordination and cross-talk within the same or even distinct
pathways.
Elucidation of the structures of a number of PDZ domains alone, or in the ligandbound state have provided valuable insights into how auxillary structural components of a
globular protein in an interaction with an adaptor protein modulate the activity of the core
domain (45). The canonical structural configuration of PDZ domains comprises 6 βstrands (βA ~ βF), a short α-helix (αA) and a long α-helix (αB). Single hydrophobic cleft
between the αB-helix and βB-strand structures, with the highly conserved carboxylatebinding loop (R/K-XXX-G-Φ-G-Φ motif, where X is any amino acid residue and Φ is a
hydrophobic residue) located before the βB strand, forms the peptide-binding site (44).
Several modes of regulation and deregulation of PDZ-dependent interactions have been
identified which include phosphorylation of the PDZ-binding motif in the target proteins,
formation of disulphide linkages with in the PDZ-proteins, occupancy of the peptidebinding cleft by an inbuilt PDZ-binding motif and allosteric inhibition (44).
With the ability of PDZ-proteins to regulate a huge web of signal transduction
events, many of them have now been implicated in cancer and neurodegenerative
disorders (46). This is based on the studies in animal models and using blocking peptides
to competitively inhibit native interactions which identified that certain PDZ-proteins
integrate disease-associated proteins. The obvious advantage of targeting scaffolding
proteins is the simultaneous control of multiple signaling cascades in complex diseases
by hitting a single protein rather than multiple disease-related proteins. Subtle-binding
specificities of PDZ-domains have been moderately classified. Also, mapping of the PDZ
domains and narrowing down to smaller binding segments would confer a high degree of
specificity and flexibility in the use of such therapeutic approaches. The bigger challenge
in the future in using PDZ-interaction modules as drug targets is the promising in vivo
outcome and the ease of manipulation of this approach without any significant side
effects.
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CFTR macromolecular complexes on PDZ-scaffolds
CFTR possesses a class I PDZ-domain binding motif DTRL-COOH at the C
terminus that mediates the binding of CFTR to several PDZ-domain proteins, including
Na+/H+ exchange regulatory factor 1 (NHERF1), NHERF2, CFTR-associated protein 70
kDa (CAP70; also known as PDZK1), NHERF4 and CFTR-associated ligand (CAL)
(47). Various PDZ-mediated interactions of CFTR and their implications are shown in
Figure 2-2.
PDZ-proteins are usually bivalent or multivalent harboring multiple PDZdomains. This structural feature of PDZ-proteins is known to contribute to CFTRdimerization and most interestingly, constitution of large multiple protein complexes
which act as hubs of enzymatic and regulatory activities (48, 49). Also, the crosslinking
between two CFTR molecules or CFTR and other interacting proteins can be modulated
by the stoichiometry of CFTR-PDZ-protein interaction (48). Few studies also suggested
that CFTR dimerization is only cAMP-regulated and does not require NHERF proteins
(50). Other roles of PDZ-mediated interactions of CFTR have been identified which
include trafficking, polarized expression and membrane-associated mobility and
stabilization of the protein (34).
CFTR is coupled to β2 adrenergic receptor signaling via the formation of a NHERF1mediated macromolecular complex with β2 adrenergic receptor at the plasma membrane
CFTR couples β2-AR via NHERF1 at the apical surface of epithelial cells (22).
NHERF1 recognizes Ezrin (an AKAP) via its ezrin/radixin/moesin (ERM) domain at the
C-terminus that positions PKA close to CFTR. On agonist activation of the receptor, AC
is stimulated generating highly compartmentalized cAMP which leads to
phosphorylation-based activation of the channel (22). In this study they also reported that
the macromolecular formation is dependent on the phosphorylation status of CFTR as it
negatively regulates the binding of the CFTR to NHERF1 and also deletion of the R
domain in CFTR cancelled dose-dependent inhibitory effect of PKA on complex
formation. In addition, impaired β2-AR-mediated regulation of CFTR function has also
been recapitulated in NHERF1 deficient mice (49). Also, highly similar proteins
NHERF2 and PDZK1 failed to compensate for β2-AR-mediated response, indicating that
complex-mediated regulation of CFTR is NHERF1 specific. It suggests that there is a
high degree of specificity associated with a compartmentalized response. It is also
predicted that such compartmentalization based signaling can get compromised in mutant
and defective CFTR protein.
A macromolecular complex of CFTR-NHERF1-NHE3 exists on the luminal surface of
pancreatic duct
An interesting component of CFTR function is regulation of luminal HCO3- levels.
CFTR function increases HCO3- secretion when stimulated and reduces HCO3-salvaging
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Figure 2-2.

CFTR and PDZ protein binding partners
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by other luminal transporters such as Na+/H+ exchanger regulatory factor 3 (NHE3) in the
resting state (51). Later, these two proteins were found to co-exist as a part of a
macromolecular complex on the apical surface of pancreatic ductal cells. CFTR in this
complex acutely mediates cAMP-monitored inhibition of NHE3 function and in a chronic
mechanism elevate expression levels of NHE3 at the plasma membrane (34, 52, 53).
NHERF1 mediates the functional coupling between CFTR and NHE3 with the first PDZ
domain of NHERF1 preferentially complexing with CFTR and NHE3 associating with
the latter half including the second PDZ domain and the C-terminal ERM binding domain
of NHERF1 (34). With NHERF1as an Ezrin binding protein, regulation of NHE3 by
PKA would be instantaneous and highly compartmentalized. Interestingly, mutant CFTR
failed to elicit inhibition of NHE3 function or increase in its expression level, implying
that an intact CFTR is required for mediating this compartmentalized regulation. Also,
the macromolecular association possibly has a significant role in stabilizing NHE3 at the
plasma membrane. This concept runs parallel to the stabilization of CFTR at the plasma
membrane by NHERF1-mediated coupling of the protein to actin cytoskeleton (54).
CFTR is engaged in an inter-domain interaction with Cl-/HCO3- exchangers on NHERF
scaffolds
The mechanism where CFTR can stimulate HCO3- secretion in the activated state
involves coupling of CFTR with Cl-/HCO3- exchangers which include members of the
SLC26 exchanger family SLC26A3/DRA and SLC26A6/PAT1. SLC26 transporters and
CFTR assemble together onto NHERF scaffolds (55, 56). Also, an interdomain
interaction between conserved sulphate transporter and anti-sigma antagonist domain of
SLC26 transporters at the C-terminal and the R domain of CFTR reciprocally modulates
activities of these transporters (57). Consequently, stimulation of DRA could increase the
open probability of CFTR by 6-fold and phosphorylation of the R domain of CFTR
resulted in an increase in DRA activity. Importantly, NHERF1 and NHERF2 scaffolding
dynamics within the complex would determine the functional output of this association
(58). This inter-regulated assembly of SLC26 transporters and CFTR channel functions
as a HCO3− flux regulating system in the apical membranes of epithelial cells.
An LPA2-NHERF2-CFTR macromolecular signaling complex downregulates CFTR
function in response to LPA
CFTR was also reported to associate with another GPCR lysophosphatidic acid
receptor-2 (LPA2) bridged by scaffolding protein NHERF2 (42). Supposedly, LPA2 in
this complex is coupled to Gαi G-protein which inhibits AC function. LPA2 is one of the
many receptors for lysophosphatidic acid, a physiological phospholipid present in the
blood (59). Therefore upon stimulation of LPA2 with LPA binding, CFTR activity within
the complex is downregulated because of the reduced flux of cAMP near CFTR. LPA2
mediated downregulation of CFTR function conferred protection against cholera toxin
(CTX)-induced secretory diarrhea in which CFTR has a predominant role (42). An
interesting component of this study was LPA did not alter the global cAMP levels in the
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presence of low concentration ADO, implying that the LPA-mediated effect via LPA2 on
CFTR channel function was highly compartmentalized. Functional consequences of LPA
on CFTR activity also suggested that diet supplementation with LPA or consumption of
an LPA-enriched diet can be considered as an alternative therapy for controlling watery
diarrhea.
Spatiotemporal coupling of CFTR and MRP4 at the apical plasma membrane
Another evidence of compartmentalized regulation of CFTR is the association of
CFTR with the cAMP/cGMP-efflux transporter multi-drug resistance protein 4 (MRP4)
mediated by PDZK1 (5). Inhibition of MRP4 generates a localized pool of cAMP in the
vicinity of CFTR allowing spatiotemporal regulation of CFTR channel function in certain
plasma membrane microdomains. Low dose adenosine in the presence of MRP4 inhibitor
MK571substantially potentiated CFTR-mediated Cl- currents. However, higher doses of
ADO (> 20 µM) failed to significantly alter CFTR function in the presence of MK571.
Mrp4-/- and Mrp4+/+ mice with inhibition of MRP4, showed ameliorated CTX-induced
diarrheal phenotype. MRP4 lines apical and basolateral surfaces of various cell-types and
its proximity to cyclic-nucleotide effectors would allow the instantaneous modulation of
their activities as it regulates the flux of cyclic messengers without the need of degrading
them.
Cyclic nucleotide extrusion by MRP4 represents a mean of maintaining cyclic
nucleotide balance inside the cell other than degradation by PDEs.
CFTR functions as a conductance regulator by coupling physically and functionally with
renal K channel
The role of CFTR as a conductance regulator other than a Cl- pump was validated
in its ability to regulate the activity of several transporters in the epithelial membranes. A
prominent example of such an ability of CFTR is the formation of a macromolecular
complex of CFTR and renal secretory renal outer medullar potassium (ROMK) channel
(also known as Kir 1.1 or KCNJ1) at the apical membrane (59). Interestingly, CFTR is
expressed throughout the nephron. CFTR-ROMK complex would regulate salt absorption
by controlling K+ recycling/secretion across the thick ascending limb of Henle’s loop,
distal tubule, and collecting duct in the kidney.
ROMK binds to NHERF scaffolding proteins which is a strong determinant of
plasmalemmal expression of active ROMK and also coordination of physical and
functional coupling between CFTR and ROMK. Primarily, this association regulates
channel sensitivity to sulfonylurea, glibenclamide and intracellular ATP. PKA activity
acts as a functional switch that determines the CFTR-mediated regulatory effects on
ROMK.
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A macromolecular signaling complex of AQP9, NHERF1, and CFTR
CF patients have major fertility issues among both men and women. The major
cause of CF-males being infertile is the anatomical absence of vas deferens and atrophied
epididymis at certain regions and, possibly it is the presence of thick and tenacious
cervical mucus which causes females to be reproductively compromised (60). It has been
shown that CFTR is not only required to developmentally regulate reproductive systems
but also for CFTR-mediated regulation of HCO3- secretion in the uterus which is critical
for the fertilizing capacity of the sperm (60). Fluid content and composition of the male
reproductive tract is critical to control sperm density and motility. CFTR has a prominent
role in regulating luminal contents in distal epididymis and vas deferens. Recently, a
NHERF1-mediated complex of CFTR with another apical protein aquaporin 9 (AQ9) was
identified in the principal cells of the epididymis and the vas deferens (61). AQ9 belongs
to a class of transporters which permeates bulk water and neutral solutes such as glycerol
across the epithelia in response to an osmotic gradient (62, 63). AQ9 lines the apical
membranes of both ciliated principle cells along the epididymis and vas deferens and
non-ciliated cells of the efferent ducts fairly co-localizing with CFTR (34). Another study
demonstrated that CFTR and AQ9 could synergistically modulate luminal fluid
composition at these regions (64). Since AQ9 could co-immunoprecipate both
phosphorylated and non-phosphorylated forms of NHERF1, the phosphorylation status of
NHERF1 would act as a determinant of the regulatory influences of CFTR on AQ9 (61).
This stems from the fact that phosphorylated NHERF1 causes CFTR to switch from its
chloride channel activity to a conductance regulator. Similar aspects of regulation hold
for the CFTR-ROMK protein complex (65).
These studies clearly suggest the potential of CFTR in engaging in multipleprotein containing signaling complexes which would ensure high fidelity and efficiency
of CFTR regulation and may also have pathophysiological relevance.
Inducible Nitric Oxide Synthase
Inducible nitric oxide synthase (iNOS or NOS2) is a 1153 amino acids long
protein which is non-constitutively expressed in many cell types and is usually
upregulated in response to an inflammatory trigger (66). In contrast to other NOS forms
which include endothelial NOS and neuronal NOS, iNOS does not get regulated by
intracellular changes in Ca2+ (67). Several cell-types such as endothelial cells,
hepatocytes, enterocytes, immune cells and smooth muscle cells can synthesize iNOS
(68).
Transcriptional activation of iNOS is under the control of the NFκB pathway
which gets stimulated in response to cytokines and lipopolysaccharides (LPS). iNOS is a
modular protein with oxygenase and reductase domains at the N-and C-terminal halves,
respectively. The oxygenase domain contains the binding site for heme, L-arginine and
tetrahydrobiopterin (BH4).The reductase domain harbors CaM, NADPH, FAD and FMN
binding regions. The structure of full-length iNOS is represented in Figure 2-3.
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Figure 2-3.

Representation of structural components of iNOS protein
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NOS synthesizes NO in a two- step oxidative conversion of L-arginine to NO and
L-citrulline in the presence of cofactors including heme, FMN, FAD and BH4 and,
NADPH as an electron donor. Also, iNOS needs to form dimers to be functionally active
and homodimerization requires binding of L-arginine, heme and BH4 (68).
Compartmentalized NO Signaling
Recent data suggests that iNOS activity, although sustained, is subject to
regulation within mammalian cells and at least 11 different proteins have been reported to
bind to iNOS (calmodulin, caveolin-1, -2, and -3, NAP110, kalirin, Rac1, Rac2, α-actinin
4, EBP50 and PDZK1) (69, 70). Besides, some of these interactions can govern the
subcellular location of the enzyme (69, 70). iNOS harbors the PDZ-domain recognizing
motif SAL at its carboxyl-terminal and therefore, can tether onto PDZ-scaffolds. iNOS
binding to EBP50 and CAP-70 are PDZ-mediated interactions and have been shown to be
critical for polarized expression (at the apical membrane) of iNOS and vectorial NO
synthesis (69, 70). NO being gaseous in nature is quite a diffusible molecule and, using
cell culture models, it has been estimated that the diffusion of NO would be in the range
of several 100 µmeters (71). However, these calculations cannot be applied to complex
biological systems as NO encounters numerous diffusion barriers inside the cell which
include interaction with NO-responsive targets, quenching of NO by superoxides to form
peroxynitrites, the partitioning of NO between polar and apolar media and exposure to
cholesterol rich biomolecules (71). NO-mediated responses concord with the varied
clinical stimuli so that the ensuing effects are diverse. This concludes that NO-generated
responses can be compartmentalized which would involve selective localization of NOSs
and the proximity of NO-responsive targets (71). Endothelial NOS was found to be
localized mainly on the golgi apparatus and membrane caveole leading to highly confined
S-nitrosylation of the target proteins (72). In certain physiological situations, certain
receptors can stimulate NO synthases. For example, the proinflammatory peptides kinins
stimulate the synthesis of NO that involves physical interaction of endothelial NOS with
kinin B1 and B2 receptors (73). Estrogen upon binding to the plasma membraneassociated estrogen receptors can excessively stimulate NO generation from eNOS (74).
Exclusive expression of iNOS on the apical membranes of the polarized epithelial cells
suggests that the luminal membrane would be more enriched with NO and NO-dependent
signaling pathways.
The most notable NO-mediated effect inside the cell is the stimulation of the
cGMP synthesizing enzyme soluble guanylate cyclase (sGC) (75). NO binds to the
attached prosthetic heme group present in sGC and induces conformational changes that
stimulate the enzyme activities. In this fashion, NO can also regulate the amounts of
cGMP inside the cell. It is also known that NO can stimulate different subtype of sGCs
generating compartmental cGMP which regulates distinct receptors in the neuronal cells
to regulate long-term potentiation and neurotransmitter release critical for synaptic
plasticity (76). Also, if NO can be compartmentalized, it would also lead to localized
cGMP generation which can be potentially important in conditions like IBD which has
remarkably increased levels of iNOS. cGMP is an important cellular messenger and can
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regulate fluid homeostasis across the epithelial cells lining small intestine and colon (77).
cGMP can stimulate CFTR Cl- channel function through kinase (PKA or PKG)-mediated
phosphorylation of the channel (77). The membrane-bound cGMP-dependent protein
kinase (cGK) type II which is predominantly expressed in intestinal epithelial cells colocalizes with CFTR and phosphorylates the channel to regulate its activity (78). Whether
microdomain cGMP generated as a consequence of NO-cGMP pathway would play a
role in CFTR regulation has not been elucidated before.
Role of CFTR in Health and Disease
Cystic fibrosis
CFTR was identified as a gene mutated in the pernicious autosomal recessive
genetic disorder cystic fibrosis (CF). CF is most prevalent among Caucasians and one in
every 3500 babies in USA would have CF. It is estimated that around 75,000 people in
the world suffer from CF. CF patients suffer from severe exocrine insufficiency causing
an obstructed mucosa especially in the lung airways. Sticky and thick mucus accumulates
in the lung which favors colonization of opportunistic bacteria including Pseudomonas
aeruginosa, Burkholderia cepacia, Staphylococcus aureus and Haemophilus influenza
(35). P. aeruginosa forms biofilms composed of macrocolonies which are resistant to
anti-microbial agents. Also, inflammatory responses get triggered accompanied by
reduced levels of anti-inflammatory cytokines and proteases. The chronic infectious
condition of the lung with the persistent deterioration of lung function becomes the major
cause of morbidity and mortality of CF patients. Other complications associated with CF
include fibrotic pancreas, pancreatic insufficiency, potentially fatal condition of the gut
(meconium ileus) in about 10% of the patients and male infertility. The best biomarker of
CF with a correlated involvement of CFTR in the disease is Cl-. Therefore, in order to
confirm if a patient has CF, salt concentration in the sweat less than 60mmol/L is
considered as intermediate- or non-CF. This is based on the hypothesis that CFTR in
sweat glands absorb Cl-. In case of a defective CFTR as in CF, Cl- fails to be absorbed
properly and therefore, forms salt. In the cases where the sweat Cl- is normal or
intermediary but the individual has CF-manifestations or bears a family history of CF, it
is necessary to confirm the possibility of having CF by measuring nasal potential
difference (NPD) (79). In CF, luminal surfaces have more negative charge either because
of the overly active Na+ absorption in the absence of CFTR or the inability to absorb Cl-.
Usually, the basal PD of CF patients is approximately two-to three-folds higher than
normal individuals (80)
There are around 1900 CFTR mutations known today but not every mutation
leads to CF (81). Any CFTR mutation which results in defective protein synthesis, halted
processing, defective trafficking, block in regulation, altered conductance or reduced
synthesis of CFTR can cause CF (82). F508Del mutation in CFTR is the most common
CF-causing mutation accounting for about 70% of the CF-underlying defects. F508Del
mutation causes CFTR to be misfolded and recognized by ER-associated degradative
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machinery. Now other defects associated with F508Del have been recognized which
include altered conductance, mislocalization, impaired post-ER trafficking, poor subapical membrane retrieval, markedly low-stability at the membrane and decreased mRNA
levels (83). Newly recognized defects with F508Del-CFTR include thermal
destabilization caused by this mutation and the impaired inter-domain interactions
between NBD1 and membrane spanning domains (84-86).
Because F508Del-CFTR is known to possess partial Cl- conductance once it
reaches the cell surface, several CF therapies have been based on the potentiation of a
small population of F508Del-CFTR present at the cell surface. The CF-potentiator VX770 is clinically approved for CF-patients carrying G551D-CFTR (exhibits a locked Clconductance) and its efficacy is being evaluated in F508Del homozygous mutant CFpatients (87). Other therapies have focused on lifting the processing defects to increase
F508Del-CFTR number at the plasma membrane. However, the clinical trial of CFcorrector VX-809 which increases the F508Del-CFTR population reaching at the surface
failed to show promising lung improvement in CF-patients although sweat Clconcentration was reduced with VX-809 treatment (88).
Interestingly, it is not only the deficiency of CFTR which leads to a pathological
condition as CFTR might contribute to the enlargement of renal cysts in individuals with
polycystic kidney disease and hyperactivity of CFTR in the gut causes infectious
diarrhea (89, 90).
Role of CFTR in fluid secretion and diarrhea
Approximately eight liters of fluid is secreted into the intestine everyday (77).
Regulation of fluid secretion is critical as enzymes and solutes need aqueous media to
diffuse and function and, also the mucosa needs to be lubricated for preventing frictional
damage during motility (77). The key to fluid secretion is how several electrolyte
transporters present on the gut epithelia are regulated. Secretion of selective electrolytes
and solutes into the lumen sets the osmotic gradient for the movement of water. It was
mostly believed that water takes the paracellular route, however recent evidences indicate
the possibility of transcellular water transport. There is a simple mechanics, very wellunderstood today, on how epithelial ion transporters function on the intestinal surface to
regulate water movement.
It is now accepted that together with Na+ absorption, Cl- secretion constitutes the
predominant driving component of fluid secretion (77). The electroneutral transporter
Na/K/2Cl (NKCC) on the basolateral membrane takes up Cl- into the cell which sets the
electrochemical potential for Cl-. When the Cl- channels on the apical surface,
(predominantly CFTR) open, Cl- gets transported into the lumen. Na+ K+-ATPase located
on the basolateral surface functions as an electrogenic transporter to maintain the thrust
for Cl- secretion out of the cell. In order to maintain electroneutrality, Na+ is secreted into
the lumen via a paracellular pathway resulting in an osmotic flux of water. The
schematics of the entire process are shown in Figure 2-4.
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Figure 2-4.

Fluid transport model in a polarized intestinal epithelial cell

Concerted actions of various transporters located on the apical and basolateral
membranes of polarized gut epithelial cells regulate fluid transport.
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It is a well-known fact now that secretory and absorptive processes along the
length of the intestine are highly asymmetric to the extent that the surface operating
mechanisms will be different than those in the intestinal crypts (77). Still, relevance of
CFTR-mediated Cl- secretion in regulation of fluid homeostasis is irrespective of the
region of the gut and cannot be discounted. In CF, the failure to secrete sufficient Clleads to dehydrated and obstructed mucosa (meconium ileus) in 10% of the neonates,
distal intestinal obstruction syndrome (DIOS), and chronic constipation in older CF
patients (91).
Secretory diarrhea is a consequence of major electrolyte transport abnormalities in
the gut mucosa. Colonization by certain pathogenic enterobacteria majorly E. coli, Vibrio
cholerae, Yersinia enterocolitica, Shigella flexneri, and Salmonella typhimurium and
their toxic secretagouges lead to secretory diarrhea (34). Given the fact that increase in
intracellular levels of cAMP, cGMP or Ca2+ activates CFTR Cl- channel function, any
molecular agent which causes unregulated increase in the levels of these messengers
would surpass the regulatory threshold on CFTR and cause fluid dysregulation such as
diarrhea. CFTR heterozygosity conferred resistance to diarrhea induced by CTX, an
enterotoxin from Vibrio cholera, which underscored the direct involvement of CFTR in
causing secretory diarrhea (90). In this study, CF-mice failed to have any secretory
phenotype in response to CTX challenge. The underlying mechanism of CTX-induced
diarrhea is irreversible ADP-ribosylation of G-protein Gαs by CTX which locks it in the
active GTP-bound state. Constitutively active Gαs stimulates AC in an unregulated
manner which pools the cell with cAMP. Excessive cAMP causes overstimulation of
CFTR activity and downregulation of Na+ absorption culminating into excessive flow of
water into the gut and diarrhea. A question of interest would be whether these
enterotoxins can be used as a therapy for CF patients to partially relieve meconium ileus?
Enterotoxins will be effective in CF patients with the condition of meconium ileus
provided they are able to stimulate CFTR-independent secretions. It is also known that
cholera toxin cannot trigger any secretion in CF mice. It is to be noted that predisposition
to meconium ileus is genetically determined and the predisposition of the CF patients to
this phenotype is variable. Also, not all CF patients have meconium ileus implying that
several other genomic loci than CFTR are also involved. A recent study reports that
guanlyl cyclase 2C encoded by GUCY2C can be a likely modifier of meconium ileus
associated with CF (92). Therefore, if the genes other than CFTR can be targeted that
improves secretion, there is a possibility that meconium ileus can be effectively
controlled.
Heat-stable enterotoxins from E. coli or Y. enterocolitica directly stimulate
membrane-bound guanylyl cyclase C (GC-C) and enhance intracellular cGMP (93).
CFTR activity gets stimulated by the efficient phosphorylation of the channel by
membrane localized cGMP-dependent protein kinase II (cGKII) which in combination
with hypoabsorption of Na+ result in diarrhea (94, 95). Also, upregulated levels of iNOS
and prostaglandin generating enzyme cyclooxygenase-2 could enhance Cl- secretion and
leakiness of epithelial junctions in a colon epithelial cell line challenged with
enteroinvasive bacteria (96). This can be the possible mechanism of infectious diarrhea
caused by these bacteria.
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Approximately 2.5 million children in the developing world die annually from
infectious diarrhea and it accounts for 21% of the causes of death of children aged under
5 years (97). Interestingly, infectious diarrhea comes next to cardiovascular disorders as a
major cause of mortality especially in the subsets of pediatric and elderly population.
With the validation of CFTR involvement in many forms of secretory diarrhea, therapies
to control diarrhea are now focused on developing drugs to block CFTR Cl- secretion in
the patients some of which are already known to be effective. The plant latex derivative
SP-303 was demonstrated to attenuate CTX-induced CFTR-dependent secretion in vitro
and its naturally occurring counterpart, derived from the latex of the plant Croton lechleri
has always been in use by natives of South America to control various kinds of watery
diarrheas. Based on the effects of LPA in downregulating CFTR function and
ameliorating diarrheal phenotype of CTX-injected mice, an LPA-rich diet can effectively
control certain forms of diarrhea. Cesinex®, a tannic acid based medical food is
prescribed for diarrheal episodes in USA and could successfully attenuate CTX-induced
diarrhea in mice (98). It is known that egg albumen has high amounts of LPA. Based on
the aforementioned studies, a formulation combining tannic acid and egg albumen can
exhibit improved anti-diarrheal properties. Also, MRP4 which couples closely with
CFTR and regulates its function in physiological and pathophysiological situations can
represent another target for therapeutic interventions of diarrheal disorders.
With a major contribution of CFTR in regulation of fluid secretion across the gut
mucosa, there is an imperative interest in the contribution of CFTR in other diarrheal
disorders including, inflammatory bowel disorders, irritable bowel disorders and
diverticulitis. However, the exact role of CFTR in contributing to diarrhea in these
disorders has not been clearly elucidated. This aspect would define the role of CFTR
under a pathological situation.
Inflammatory Bowel Disease
Inflammatory bowel disorders (IBD) represent chronic relapsing inflammatory
condition of the gastrointestinal tract (GI) and are broadly categorized into ulcerative
colitis (UC) and Crohn’s disease (CD). UC extends proximally from the rectum and is
restricted to the colon mucosa while CD is transmural and can affect any part of the GI
tract (99). IBD patients suffer from diarrhea, abdominal pain, and weight loss and with
long persistence are predisposed to an increased risk of developing colorectal cancer
(100). More than one million people world-wide suffer from IBD and it is also the major
cause of morbidity in the western world. The etiology of IBD is understood to be
multifactorial and the precise onset of IBD is still not established (101). In particular, a
compromised epithelial barrier in the intestine of genetically predisposed IBD patients
supposedly cause commensal intestinal flora to trigger innate inflammatory response,
thus leading to the disease. Therefore, IBD is often described as an autoimmune disorder.
Diarrhea is the most common and distressing symptom in IBD patients often
‘bloody’ with a 50% consistency in acute flare-ups of CD and almost 100% of UC
patients (102). IBD patients have varied diarrheal manifestations leading to an unresolved
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conclusion about the mechanism of diarrhea in IBD. It is critical to define the precise
pathophysiologic mechanisms of diarrhea in IBD patients to effectively control it.
Electrolyte transport abnormalities in IBD
It is an accepted fact that IBD patients have disturbed electrolyte transport.
Inflammatory secretagogues present in the supernatant of inflamed human colonic
mucosa could stimulate electrogenic Cl- secretion in rat colonic mucosa in Ussing
chambers which suggested that Cl- secretion is probably altered in IBD (103). However, it
did not reconcile with the observed diminished intrinsic responsiveness of the mucosa to
the secretory stimuli and loss of the lumen-negative potential difference (PD) (103, 104).
There were reports on the reduced cAMP-mediated secretory response of the inflamed
mucosal tissue which may not necessarily have to do with the defects in the cAMP
pathway or cAMP-responsive proteins but with the type of cAMP-elevating ligands or
the receptor profile of the ligands used (103). Alterations in the expression and function
of CFTR in IBD have not been determined with reproducibility (103). Genetically, it has
been determined that the carriers of the loss-of-function mutation of CFTR, F508Del are
8-times less likely to develop IBD (105). However, conclusive data on the phenotypic
role of Cl- secretion and CFTR in IBD-associated electrolyte abnormalities is lacking.
CFTR-function is the rate-limiting determinant of luminal fluid levels also considering
the fact that it regulates the function of several other transporters and channels including
Na+/H+ exchangers, anion exchangers, sodium-bicarbonate transporters, K+ channels,
epithelial sodium channel (ENaC), ATP-release channels, gap-junctional channels and
aquaporins (47, 106). The regulation mostly happens in the form of large macromolecular
signaling complexes of CFTR. Therefore, it is critical to precisely define the role of
CFTR in IBD-associated diarrhea and if macromolecular complexes of CFTR would play
a role in it.
iNOS in inflammatory bowel disease
Pertaining to the blatant inflammatory profile of IBD, the therapeutic approaches
for IBD have been mostly based on targeting inflammatory mediators. iNOS which has
been found to be elevated in IBD mucosa has also been studied as a therapeutic target in
animal models of experimental colitis. Colonic mucosa of IBD patients have two to fivefold higher amounts of NO compared to those in the controls or in the mucosa of
remitting UC patients. This correlates with the increased expression and activity of iNOS
(107, 108). The correlation between iNOS activity and disease activity has been less
consistent for CD (109). iNOS has also been linked to UC disease susceptibility in the
Spanish population subset (110). iNOS in contrast to other NOS isoforms causes
sustained NO production in the µmolar range (75). Excessive NO inside the cell causes
oxidative stress (by forming peroxynitrites-ONOO-) and may also lead to the formation
of potential carcinogens (75, 111, 112). Oxidative stress has been shown to substantially
lead to mucosal injury that compromises the barrier integrity rendering it leaky.
Excessive NO/ONOO- activity has been demonstrated to cause cytoskeletal nitration and
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oxidation in the intestinal mucosa from IBD patients (113). The toxic megacolon, a
potentially lethal manifestation of UC, has also been associated with the presence of large
amounts of iNOS in the colonic muscularis propria and it was also reported that
administration of iNOS inhibitor L-NAME helped patients recover from megacolon (75,
114). The drug named mesalamine given to the IBD patients can scavenge peroxynitrites
generated as a consequence of sustained iNOS activity and can attenuate apoptosis (75).
Animal models of inflammatory bowel disorders
Inflammatory bowel disease has a complicated etiology and more than 60 animal
models are available to study IBD. These IBD models have provided significant
contributions in dissecting out various mechanisms contributing to the development of
the disease and further channel it into therapeutic interventions of IBD. IBD mouse
models have been primarily classified into gene knockout (KO) models, transgenic
models, chemically-induced colitis models and adoptive cell transfer models (115).
Induction of intestinal inflammation in mice by chemical irritation is one of the most
commonly used approach because it is simple, inexpensive, and less time-consuming and
the onset, duration, and severity of the inflammation can be easily controlled (116). The
dextran sulphate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS) induced colitis
are the most popular animal models of chemically-induced mucosal inflammation (116).
Several studies have validated the evaluations of DSS-induced colitis model to be
extended to translational studies of human. This model gives the flexibility of inducing
acute, chronic, or relapsing conditions of colitis by changing the concentration and
duration of administration of DSS (116). DSS is a sulfated polysaccharide permeable to
mucosa and causes epithelial injury (116). Animals are fed continuously with 2–5% DSS
in the drinking water for short period (4–9 days) in order to induce acute colitis and the
symptoms usually appear from the 4th day onwards (117). It is considerably important to
take into account the molecular weight of DSS to be used as it governs the severity,
extent, localization of colitis and also colitis-induced dysplastic lesions (116). Clinical
manifestations of acute DSS colitis closely mimic IBD-like symptoms and include weight
loss, diarrhea, rectal bleeding; however, in many cases animals eventually die (75, 116,
117). Typical histopathology of acute DSS-colitis is characterized by mucosal damage,
cryptitis, crypt abscesses and neutrophil infiltration of lamina propria (116, 117). As the
DSS colitis gets chronic, the inflammatory profile becomes less representative of IBD
and partially loses histopathological features of large bowel in IBD (116). Based on the
numerous advantages that DSS colitis model offers and the close resemblance it bears to
IBD, the model can prove invaluable in order to study the epithelial ion transport
abnormalities in colitis and the contribution of selective channels in causing diarrhea.
TNBS is dissolved in ethanol and the ethanol enema causes disruption of the
mucosal barrier and the TNBS chemical penetrates into virtually all layers of the intestine.
Consequently, granuloma infiltrates can be observed transmural. The colitis seen in this
model is a Th type-1 response which mimics a CD background (115).
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Specific Aims
The unifying hypothesis of my study is that excessive amounts of inducible nitric
oxide synthase (iNOS) are expressed at the apical plasma membrane of the gut epithelia
in inflammatory bowel disease where iNOS physically and functionally couples with
cystic fibrosis transmembrane conductance regulator (CFTR; a cGMP-activated Clchannel) and potentiates its Cl- channel function through stimulation of NO-cGMP
pathway. Schematics of the hypothesis are shown in Figure 2-5.
The specific aims of the study were to answer the following questions:


Is iNOS overexpressed and does it exhibit highly polarized expression in the gut
epithelial cells of IBD-affected tissue?



Is iNOS involved in a high affinity interaction with PDZ-protein NHERF2 at the
apical plasma membrane of pathophysiological relevance?



Does NHERF2 bridge CFTR and iNOS in a form of macromolecular signaling
complex?



Does iNOS contribute to microdomain cGMP at the plasma membrane via the
potentiation of the NO-cGMP pathway?



Does iNOS-induced compartmentalized cGMP potentiate CFTR Cl- channel
function at the plasma membrane in IBD?



Does inhibition of CFTR and iNOS activities confer resistance to colitisassociated diarrhea?



Does compromise of the macromolecular complex among CFTR, NHERF2 and
iNOS ameliorate diarrhea in colitis models? Is diarrhea attenuated in DSS and
TNBS colitis models in a Nherf2 -/- genetic background?

23

Figure 2-5.

Model of the hypothesis

The molecular machinery of how a macromolecular complex of CFTR and iNOS
contributes to diarrhea in inflammatory bowel disease.

24

CHAPTER 3.

METHODS

Reagents
Zaprinast was purchased from Enzo Life Sciences (Farmingdale, NY), and DSP
was obtained from Pierce (Thermo Fisher, Rockford, IL). Bacterial LPS was purchased
from Sigma-Aldrich (St. Louis, MO), and recombinant human TNF-α, IL-1β, and IFN-γ
were obtained from BD Biosciences (Franklin Lakes, NJ). Dextran sodium sulfate (DSS;
MW 36,000-50,000) was purchased from MP Biomedicals (Irvine, CA).
Cell Culture and Transfections
HEK-293 and HT29-CL19A cells were cultured in DMEM-F12 and DMEM high
glucose media, respectively (Invitrogen, Carlsbad, CA) containing 10% serum and 1%
penicillin/streptomycin and maintained in a 5% CO2 incubator at 37oC. Lipofectamine
2000 (Invitrogen, Carlsbad, CA) was used to express various plasmids in HEK-293 cell
lines according to the manufacturer’s instructions. Stable cell lines were generated by
lentiviral transfection and selected with puromycin (2 µg/ml).
Purification of Flag- and HA-iNOS, and GST-His-S-and His-S-iNOS-C-tail Proteins
HEK-293 cells stably expressing hemagglutinin (HA)-iNOS were plated on 100
mm dishes, and grown till 100% confluency. The cells were then washed with PBS twice
and lysed with PBS containing 0.2% Triton-X-100 and protease inhibitor cocktail
(phenylmethylsulfonyl fluoride 1 mM, pepstatin-A 1 μg/ml, leupeptin 1 μg/ml, aprotinin
1 μg/ml). The cell lysate was mixed on a shaker for 10 min at 4°C and centrifuged for 10
min at 13,000 rpm. The supernatant containing total protein was immunoprecipitated
using α-Flag or α-HA beads overnight. The beads with bound protein were washed and
the protein was eluted with 100 mM glycine (pH 2.2) and quickly neutralized with 150
mM tris (pH 8.8). The eluted protein was subjected to SDS-PAGE on 4-15% gel (BioRad, Hercules, CA) and transferred to PVDF membrane and either visualized with Gel
Code Blue or immunoblotted with α-Flag-HRP or α-HA-HRP antibody.
For the purification of GST-His-S- or His-S-tagged iNOS-C-tail, pET-41- and
pTriEx-4-iNOS-C-tail constructs were used to transform BL21 and Origami competent
cells, respectively. Bacterial cultures (1L) were grown and the protein synthesis was
induced with IPTG (0.2 mM) for 4 h. For GST-tagged and His-tagged proteins lysis
buffer comprising of 50 mM Tris, 1 mM EDTA and 10% Sucrose pH7.2 and
resuspension buffer containing 25 mM HEPES-KOH, 400 mM KCl and 5 mM βmercaptoethanol (added fresh) respectively, was used followed by addition of lysozyme
(1mg/ml) prepared in lysis or resuspension buffer for 30 min at 4°C. Next, 2.1% TritonX-100 was added to the lysate and mixed for another 30 min at 4°C. Lysate was
transferred to clean centrifuge tubes and spun at 15,000 rpm for 30 min at 4°C. To the
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clear supernatant 100 µl of Glutathione beads (Thermo Scientific, Waltham, MA) or
Talon-beads (Clontech, Mountain View, CA) were added as appropriate and mixed for 23 h at 4°C. Glutathione beads and Talon beads containing proteins were washed threefour times with PBS 0.2% Triton-X-100 and resuspension buffer; respectively in the
presence of protease inhibitors. GST-His-S-iNOS-C-tail and His-S-iNOS-C-tail proteins
were eluted with 20 mM glutathione and 200 mM imidazole, respectively for 1-4 times.
Protein concentrations of the samples were quantified using Bradford assay or by direct
absorbance at 280 nm.
PDZ-array
Purified GST-NHERF1/NHERF2/PDZK1 PDZ proteins were immobilized on
nitrocellulose membrane in various concentrations using a slot blot applicator. Purified
GST-His-S-iNOS-C-tail (100 ng) protein was added to the membrane in 0.1% Tween 20,
2% BSA with protease inhibitors for overnight binding at 4°C. Next day, the membrane
was washed extensively with TBS 0.1% Tween-20 and probed with S-HRP antibody.
Pull-down Assay
HEK-293 cells overexpressing HA-iNOS were lysed in lysis buffer (PBS 0.2%
Triton X-100 + protease inhibitors). Cell lysates were mixed for 15 min followed by
centrifugation at 15,000 g for 10 min at 4°C. GST-NHERF2 was added and mixed at 4°C
with the clear supernatant for 30-60 min. Glutathione beads (20 μl) were then added and
mixed overnight at 4°C. Thereafter, the mixtures were spun at 3000 rpm for 2 min, and
the beads were washed three times with the same lysis buffer before the proteins were
eluted from the beads with the sample buffer (containing 2.5% β-mercaptoethanol).
Eluates were separated on 4-15% gel and immunoblotted with mouse monoclonal αiNOS antibody (BD Biosciences, Franklin Lakes, NJ).
In the next set of assays, HEK-293 cells overexpressing iNOS and iNOS-∆PDZ or
mucosal scrapings from DSS-treated and untreated colons were lysed in lysis buffer (PBS
containing 0.2% Triton X-100 and protease inhibitors), mixed for 15 min followed by
centrifugation at 15,000 rpm for 10 min at 4°C. GST-NHERF2 was added and mixed at
4°C with the clear supernatant (~ 500 µg) for 30-60 min. Glutathione beads (20 μl) were
then added and mixed overnight. Thereafter, the mixtures were spun at 3000 rpm for 2
min, and the beads were washed three times with the same lysis buffer before the proteins
were eluted from the beads with the sample buffer (containing 2.5% β-mercaptoethanol).
For the tissue pull-down, proteins were eluted with100 mM glycine (pH 2.2) and quickly
neutralized with 150 mM Tris (pH 8.8). Eluates were separated on 4-15% gel and
immunoblotted with mouse monoclonal α-iNOS antibody and rabbit polyclonal 1314
CFTR antibody.
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Co-immunoprecipitation
HA-iNOS-HEK-293 and control-HEK-293 cells were incubated with the crosslinker dithiobis succinimidyl propionate (DSP, 1 mM) for 10 min at 37°C. Cells were
then lysed using lysis buffer-1X PBS, containing 0.2% Triton-X-100 and protease
inhibitors and the clear supernatant was subjected to immunoprecipitation by using HAbeads (Sigma-Aldrich, St.Louis, MO) for overnight at 4°C. The cross-linked complex
was eluted with 100 mM glycine (pH 2.2) and quickly neutralized with 150 mM Tris (pH
8.8). The eluted proteins were mixed with the sample buffer (5X; containing 1% βmercaptoethanol), denatured, subjected to SDS-PAGE, transferred to PVDF membrane,
and immunoblotted using rabbit polyclonal α-NHERF2 antibody.
Direct Sensitized Fluorescence Resonance Energy Transfer Microscopy and Data
Analysis
For direct sensitized emission FRET, HEK-293 cells were transiently transfected
with pECFP-iNOS, YFP-CFTR, Yellow-NHERF2, pCMV-HA-NHERF2 either singly or
in combination using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Single transfected
cells were used to acquire CFP- or YFP- only images for bleedthrough calculations. The
cells were maintained at low density (20-40% confluence) on a cover slip bottom dish
(MatTek; Ashland, MA), washed twice with warm HBSS and 2 ml of HBSS was added.
Cells were imaged in a dark room at 37°C. Corrected FRET was calculated on a pixel-bypixel basis for the entire image by using equation: FRETc = FRET - (0.5 × CFP) - (0.06 ×
YFP), where FRET, CFP, and YFP correspond to background-subtracted images of cells
co-expressing CFP-iNOS and YFP-CFTR/Yellow-NHERF2 acquired through the FRET,
CFP, and YFP channels, respectively. The factors 0.5 and 0.06 are the fractions of bleedthrough of CFP and YFP fluorescence, respectively, through the FRET filter channel.
The corrected FRET (FRETc) was normalized with donor CFP intensity (FRETc/CFP),
yielding the normalized corrected FRET (N-FRETc), and the intensity of N-FRETc
images was presented in monochrome mode, stretched between the low and high
renormalization values, according to an intensity to color mapped lookup table with black
indicating low values and white indicating high values. All calculations were performed
using the Channel Math and FRET modules of the SlideBook 4.2 software (Intelligent
Imaging Innovations; Denver, CO).
AlphaScreen™ Assay for iNOS-NHERF2 Interaction
We used AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay)
to study the interaction between purified full-length GST-NHERF2 and biotin-iNOS-Ctail peptide (last 10 amino acids), using AlphaScreen™ GST Detection Kit (PerkinElmer,
Waltham, MA). In brief, starting from 300 µM concentration, biotin-iNOS-C-tail peptide
was serially diluted (in 1/2 log dilution series) in assay buffer [1x HEPES, 0.1% BSA,
0.05% Tween 20 (v/v), pH 7.2] containing GST-NHERF2 (100 nM final concentration).
For the interaction between His-S-iNOS-C-tail and GST-NHERF2, similar procedure was
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followed with the starting concentration of 100 nM for His-S-iNOS-C-tail with
progressive dilution and 100 nM final concentration for GST-NHERF2. The resulting
solutions were incubated at room temperature for 30 min. Each sample solution (15 μl)
was transferred to a white opaque 384-well microplate (OptiPlateTM-384; PerkinElmer,
Waltham, MA) in triplicates and into which anti-GST acceptor beads (5 μl, 20 μg/ml
final concentration) were added and incubated for 30 min at room temperature.
Streptavidin donor beads (5 μL; 20 μg/ml final concentration) were then added and
incubated for 2 h at room temperature. Anti-GST acceptor beads (5 μl, 20 μg/ml final
concentration) and Nickel chelate donor beads (5 μl, 20 μg/ml final concentration) were
used for GST-His-S-iNOS-C-tail and GST-NHERF2 interaction. The plate was read on
FLUOstar-Omega plate reader (Ortenberg, Germany).
The specificity of the observed AlphaScreen™ binding signals between biotin–
iNOS-C-tail peptide and GST–NHERF2 protein was verified by AlphaScreen™
competition assay. The assay procedure is similar to the association assay described
above except that a non-biotinylated iNOS peptide was serially diluted in the assay buffer
starting with 1 mM final concentration and mixed with GST–NHERF2 (100 nM final
concentration).
Macromolecular Complex Assembly
GST-His-S-iNOS-C terminal 112 a.a. fusion protein (20 μg) was mixed with
various amounts of GST-NHERF2 (0-20 μg) at 4°C for 1 h, followed by mixing with
Sepharose beads (20 μl) for another 1 hr. This step, which is called pairwise binding, was
done in 200 μl of lysis buffer (1X PBS-0.2% Triton X-100 + protease inhibitors). The
complex was washed twice with the same buffer and allowed to incubate overnight with
0.5 μg purified Flag-CFTR at 4°C with constant mixing. The complex was washed
extensively with lysis buffer, eluted with sample buffer, and immunoblotted with FlagHRP antibody.
DSS-induced Colitis Murine Model
C57BL/6 male mice, 7-8 weeks old, were fed with 5% DSS in drinking water for
7 days and euthanized later. The control mice were fed with autoclaved water.
In order to evaluate the contribution of CFTR in DSS-induced diarrhea, CFTR
inhibitor CFTRinh-172 (150 µg/kg) prepared in saline was administered intraperitoneally
on the 5th day of DSS-treatment following appearance of symptoms of colitis and was
given twice per day for 3 days. On the 8th day mice were sacrificed and colon tissue was
removed and assessed for total length, rectal bleeding score using ColonScreen-ES
(Helena laboratories, Beaumont, TX), wet/dry weight ratio and histological examination.
Dry to wet weight ratio was calculated by drying fecal pellets from the colon at 50°C
overnight.
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iNOS inhibitor L-NIL (N6-(1-Iminoethyl)-L-lysine dihydrochloride) (Cayman
Chemical, Ann Arbor, MI) known to be highly selective for iNOS was administered
intraperitoneally at a concentration of 10mg/kg/12 h for 6, 4 and 2 days in three different
mouse groups treated with 5% DSS containing four animals per group. Saline was
administered in the control animals.
TNBS Colitis Murine Model
TNBS colitis was induced by a single rectal injection of 3.75 mg of TNBS
dissolved in 50% ethanol-PBS solution into the descending colon of C57BL/6 male
Nherf2 -/- and Nherf2 +/+ mice using a catheter inserted up to 3-4cm into the anus. The
volume of TNBS enema was kept at 100 µl. The mice were anesthetized with
intraperitoneal injection of xylazine-ketamine solution (50 mg/kg). The animals were
observed for 3 days with regular weight measurements, and afterwards euthanized for
further assessment.
Determination of Clinical Scores
Stool consistency and the presence of occult blood were determined on day 7 of
DSS treatment. Stool consistency for TNBS-colitis was determined on day 3. Briefly,
stool scores were determined on the scale of 0 to 5 depending upon the looseness of the
fecal matter with, 0 = well-formed pellets that did not stick to the anus, 1= semi-formed
stools that did not stick to the anus, 2-4= depending upon the fluidity of the fecal matter
that did not stick to the anus and 5= non-standing liquid stool. Bleeding scores were
determined as follows: 0 = no blood, 1 = positive hemoccult, 2-4 = based on significance
of visible blood traces in the stool, 5 = gross rectal bleeding.
Histopathology Scoring for DSS Colitis
After day 7, the entire colon was excised to measure the length of the colon.
Colons were washed, fixed in formalin and embedded in paraffin. Tissue sections were
stained with hematoxylin & eosin (H&E). Histology was scored by a pathologist in a
blinded fashion based on combination of inflammatory cell infiltration (score 0–3) and
tissue damage (score 0–3) as described previously (118). The presence of occasional
inflammatory cells in the lamina propria was scored as 0, increased numbers of
inflammatory cells in the lamina propria was assigned score 1, confluence of
inflammatory cells extending into the submucosa was scored as 2, and transmural
extension of the infiltrate was scored as 3. For tissue damage, no mucosal damage was
scored as 0, lymphoepithelial lesions were scored as 1, surface mucosal erosion or focal
ulceration was scored as 2, and extensive mucosal damage and extension into deeper
structures of the bowel wall was scored as 3. The combined histological score ranged
from 0 (no changes) to 6 (extensive infiltration and tissue damage).
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Human Colon Sections
We used 5-micron thick sections of normal and IBD-affected, paraffin-embedded
human gut tissues. These slides were made available by the Tissue Service Core,
Pathology Department (University of Tennessee Health Science Center) under the IRBapproved protocol 05-03854-XM. These samples and preexisting tissue from normal and
IBD individuals were de-identified.
Human mRNA Expression Data Set
The mRNA expression data set was downloaded from the NCBI Gene Expression
Omnibus database (accession number GSE1710) (119). This data set contains 31
samples generated from 10 patients with CD, 10 patients with UC, and 11 normal
controls. Data sets were log-transformed and then normalized by Zipf's law. The
normalized mRNA expression values of iNOS, CFTR, and NHERF2 were extracted from
the data set.
Immunohistochemistry
Paraffin-embedded human and mouse colon sections were stained for iNOS as
follows. Certain colon sections from mouse were embedded in a swiss-roll configuration
for better visualization. Slides were deparaffinized in xylene three times, 5 min each,
followed by dehydration with ethanol. Antigen retrieval was done with Borg DeCloaker
RTU (Biocare Medical, Concord, CA) in a pressure cooker for 5-10 min. Slides were
cooled for 5 min, and tissues were permeabilized with 0.2% Triton-X-100 in PBS for 10
min. Tissues were then blocked in 2.5% horse serum for 2 h or overnight. Slides were
rinsed with 1X PBS and incubated with rabbit polyclonal iNOS (abcam, Cambridge, UK
; 1:100 to 1:150), rabbit polyclonal R3194 CFTR(1:100) and rabbit monoclonal NHERF2
(Cell signaling, Danvers, MA; 1:50) antibodies at 4°C overnight. Slides were incubated
with peroxidazed 1 (Biocare Medical, Concord, CA) to block endogenous peroxidase
activity for 5 min. Biotin-conjugated rabbit horseradish peroxidase antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) was used in 1:100 dilution for 30 min, and
Vectastain ABC reagent (Vector labs, Burlingame, CA) was used for signal amplification
for another 30 min. Slides were developed with 3-3’-diaminobenzidine solution (Biocare
Medical, Concord, CA) according to the manufacturer’s instructions. For histological
examination, slides were lightly stained with hematoxylin and eosin. For
immunofluorescence, polarized HT29-CL19A cells were fixed in 4% formaldehyde and
permeabilized with 0.2% Triton-X-100 in PBS for 10 min. Cells were blocked in 5%
BSA in PBS for 2 h and incubated with rabbit polyclonal R3194 CFTR (1:100) and
mouse monoclonal iNOS (BD Biosciences, Franklin Lakes, NJ; 1:100 primary
antibodies) at 4°C overnight. Rabbit Alexa-fluor-488 and mouse Alexa-fluor-568
(Invitrogen, Carlsbad, CA) were used (1:100), cells were mounted, and images were
taken with a Carl Zeiss confocal microscope (Thornwood, NY). The images were
analyzed with ImageJ software (NIH; http://rsb.info.nih.gov/ij/).
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Total Internal Reflection Fluorescence Microscopy
Human colon tissue slides were immunostained for iNOS using rabbit polyclonal
iNOS primary antibody from abcam and rabbit Alexa-fluor-488 secondary antibody.
TIRF images were taken using inverted Olympus microscope with a 100X oil objective.
Antibody coupled dye was excited at 488 nm and images of emitted fluorescence were
captured at a resolution of 128 x 128 pixels (1 pixel = 0.33 µm) with EM-CCD camera.
Proximity Ligation Assay
Paraffin-embedded human colon sections were used for performing proximity
ligation assay (Olink Bioscience, Uppsala, Sweden). Briefly, human colon sections were
deparaffinized and incubated with mouse monoclonal iNOS (BD Biosciences; 1:100) and
rabbit monoclonal NHERF2 (Cell Signaling; 1:50) primary antibodies at 4°C overnight.
Next day, PLA was performed with anti-rabbit (plus) and anti-mouse (minus) Duo link In
Situ PLA probes on the tissue slides following manufacturer’s instructions. Next day,
images were taken using Zeiss LSM-5 Pascal confocal microscope.
Measurement of CFTR-mediated I- Influx Using a YFP-based Halide Sensor
HEK-293 cells with different protein expression profiles were co-transfected with
pCDNA3-TM-Cl sensor. After 24 h, the transfected cells were seeded in 12-24-well
plates and cultured for another 24 h. The cells were washed twice with 200 µl 136 mM
NaNO3 solution per well prepared in the wash buffer containing 137 mM NaCl, 4.5 mM
KH2PO4, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 5 mM HEPES, pH 7.2 and 100 µl
of the same buffer was added to each well. Fluorescence readings were recorded at 37 °C
on a FLUOstar-Omega (BMG Labtech; Ortenberg, Germany) microplate reader equipped
with HQ500/20X (500 ± 10 nm) excitation and HQ535/30M (535 ± 15 nm) emission
filters and two syringe pumps. Intracellular YFP fluorescence was monitored
continuously for 90-150 intervals 1 second each for each well. At 5 s after the start of
fluorescence recording, 100 µl of an influx buffer (272 mM NaI in the wash buffer)
containing 250 µM zaprinast was added to activate CFTR-mediated I- influx.
Iodide Efflux Assay
CFTR-mediated halide efflux was measured using an iodide efflux assay. For the
induction of iNOS levels, the following cytokine composition (cytomix) was used: TNFα 10U/ml, IFN-γ 200U/ml, LPS 1µg/ml, IL-1β 1µg/ml. HT29-CL19A cells grown on 60
mm dishes were incubated with the cytomix for 48 h. HT29-CL19A cells, which were not
treated or treated with the cytomix, were subjected to iodide efflux assay as previously
described (4). Briefly, cells were loaded for 60 min at room temperature with loading
buffer (136 mM NaI prepared in the buffer with the following composition: 137 mM
NaCl, 4.5 mM KH2PO4, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 5 mM HEPES, pH
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7.2). Extracellular NaI was washed away thoroughly (5-7 times) with efflux buffer (136
mM NaNO3 prepared in the buffer as mentioned before replacing 136 mM NaI in the
loading buffer) and then, cells were equilibrated for 1 min each for four times to establish
a stable base line in efflux buffer alone. After establishing basal equilibrium with the
nitrate buffer, cells were treated with 1mM L-Arginine for 15 min followed by zaprinast
(500 µM) to activate CFTR function. The iodide concentration of each aliquot collected
at 1 min interval was determined using an iodide-sensitive electrode (Thermo Scientific,
Waltham, MA) and converted to iodide content (nanomoles/min).
Short-circuit Current Measurements
Polarized colon epithelial cell (HT-29CL19A) monolayers were grown on Costar
Transwell permeable supports (Cambridge, MA; filter diameter 6.5 mm) until the
monolayers reached confluency and a resistance of ~1500 ohms. HT-29CL19A cells
were pretreated with or without the cytomix with the composition as mentioned before
for 48 h and the transwells were mounted in an Ussing chamber. Short-circuit currents
were measured as described previously (5). Epithelial cells were bathed in Ringer’s
solution (mM) (Basolateral side: 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3
CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 glucose, pH 7.2, [Cl-] = 149), and low ClRinger’s solution (mM) (Apical side: 133.3 Na-gluconate, 5 K-gluconate, 2.5 NaCl, 0.36
K2HPO4, 0.44 KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 10 mannitol, pH
7.2, [Cl-] = 14.8) at 37°C, and saturated with 95% O2 and 5% CO2. A 2 mV pulse was
applied every 1 min throughout the experiment to check for the integrity of the epithelia.
After stabilization of basal Isc Cells were treated with 1mM L-Arginine for 15 min
followed by adding zaprinast (100-500 μM) to the basolateral side. CFTRinh-172 (20-50
μM) was added to the apical side at the end of the experiment to verify that the shortcircuit currents were CFTR-dependent.
Ratiometric Fluorescence Resonance Energy Transfer Microscopy and Data
Analysis
For ratiometric FRET, HEK-293 cells were grown on glass-bottom dishes
(MatTek, Ashland, MA) and transfected with pcDNA3-empty vector, pcDNA3-iNOS,
and pcDNA3-m-cygnet 2.1 using Lipofectamine 2000. Cells were washed twice with
Hank’s balanced salt solution (HBSS) and mounted on an inverted Olympus wide-field
microscope (IX51, U-Plan Fluorite 60x 1.25 NA oil-immersion objective) for FRET
imaging. The stage was maintained at 37°C constantly, and the cells were maintained in
the dark in HBSS. After establishing the baseline, zaprinast was added as indicated.
Ratiometric FRET imaging was performed as described previously (5). Time-lapse
images were obtained with 1x1 binning, 100-300 ms exposure time and 1 min intervals.
Images were acquired using an EM CCD camera (Hamamatsu) mounted on an Olympus
IX51. The light source used was 300W xenon lamp with a neutral density filter. A JP4
CFP/YFP filter set was used for image capture (Chroma, Brattleboro, VT) which includes
a 430/25 nm excitation filter, a double dichroic beam splitter and two emission filters
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(470/30 nm for CFP and 535/30 nm for FRET emission) alternated by filter-change
controller Lambda 10-3 (Sutter instruments, Novato, CA). Slidebook 4.2 software was
used for data analysis. Following background subtraction, multiple regions of interest
(10-20) were selected (3-5 cells) for data analysis using ratio module. The emission ratio
(CFP/FRET) was obtained from CFP and FRET emission of background subtracted cells.
Co-immunoprecipitation in Colon Tissue
To immunoprecipitate CFTR and NHERF2 from DSS-treated mouse colon, rabbit
polyclonal iNOS antibody (1µg) was mixed with 20 µl protein A/G agarose for 1 h at
4°C. Rabbit polyclonal non-immune IgG (1µg) was used as control. Bound IgG was
washed once with 1ml 0.1M N-ethyl morpholin (NEM; pH 7.5) buffer. The IgG is cross
linked to protein A/G agarose using 10mM Dimethyl pimelimidate (DMP; Pierce Chem.
Co. Dallas, TX) in NEM buffer for 30 min at 22°C. The cross-linking reaction is stopped
by washing the beads once with 100mM Tris-base (pH 8.0). The cross-lined beads were
incubated with the lysate (1mg) in 1x PBS, containing 0.2% Triton X-100 overnight at
4°C. Next day, proteins were eluted using glycine buffer pH 2.2. Proteins were subjected
to SDS-PAGE and probed with the respective antibodies.
Real-time PCR
Total mRNA was isolated from HT-29CL19A cells (untreated or pretreated with
cytomix) using RNeasy kit from Qiagen (Hilden, Germany). The RNA was treated with
DNase I at 37°C for 1 h, and the concentration of each sample was measured using
NanoDrop (Thermo Scientific, Waltham, MA). DNA-free RNA (1 µg) was converted to
cDNA by using Transcriptor first-strand cDNA synthesis kit (Roche, Basel, SUI)
according to the manufacturer’s instructions. Real-time PCR reaction was performed
using TaqMan® probe based method in the LightCycler 480 instrument (Roche, Basel,
SUI). Probes and primers were designed using universal probe library (Roche). The target
genes were normalized with the TBP gene (probe 3). The following probes and left and
right primers were used for real-time PCR amplification of each of the genes:
iNOS (probe 37)
Left: ACCAGTACGTTTGGCAATGG
Right: TCAGCATGAAGAGCGATTTCT
CFTR (probe 8)
Left: CACAGCAACTCAAACAACTGG
Right: TGTAACAAGATGAGTGAAAATT
NHERF2 (probe 24)
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Left: TCCGAAGCTGGCAAGAAG
Right: ATAGCCCTGAGGTCCCTTTC
cGMP Assay
Mice colons were quickly frozen in liquid nitrogen and ground to a fine powder.
Tissue was dissolved in 600 µl of 6% trichloroacetic acid (TCA) and spun at 10,000 rpm
at 4°C. Pellet was lysed in lysis buffer (Tris-Cl EDTA containing 0.5% Triton-X-100 and
0.1% SDS) and the supernatant was used for protein quantitation and further processing.
Supernatant was then transferred to a glass vial and washed three times with water
saturated ether (1:1) with water forming the top phase. Sample of interest exists in the
water phase and is taken out from the top after each wash. Residual ether was removed
by boiling the samples briefly at 68°C. Samples were used for cGMP measurement by
direct cGMP ELISA from Enzo Life Sciences (Farmingdale, NY) as per manufacturer’s
directions. A cGMP standard provided in the kit was run in parallel for the quantitation of
cGMP in the samples.
NO Assay
Colon tissue was homogenized in 1ml of 1X PBS 0.2% Triton-X-100 buffer and
protein concentration of the supernatant was determined. 100 µl of the tissue supernatant
was mixed with equal volume of Griess reagent and incubated for 20 min. Plate was read
at 540 nm and the nitrite levels were determined using a sodium nitrite standard curve.
Nitrite levels were normalized with the total protein concentration.
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CHAPTER 4.

RESULTS

Purification of Full-length and Truncated iNOS Proteins
In this part of the study, affinity epitope-tagged full-length iNOS proteins
involving Flag and HA tags at the N-terminal were first cloned into pcDNA3 vector.
These constructs were primarily used for protein purification, performing biochemical
protein-protein interaction assays like pull-down assays and co-immunoprecipitation.
Also, Flag- and HA-iNOS were cloned into pLenti destination vector. pLenti-Flag- and
HA-iNOS were later used for making stable cell lines after initial selection on 6 µg/ml
puromycin for 1 week till only positive cells survived and later, trypsinized and
maintained on 2 µg/ml puromycin containing DMEM F-12 media. Five to six 100 mm
dishes of cells expressing Flag- or HA-iNOS were maintained till complete confluence.
The cells were then washed with 1 XPBS twice and lysed with PBS containing 0.2%
Triton-X-100 and protease inhibitor cocktail. The cell lysate was mixed on a shaker for
10 min at 4°C and centrifuged for 10 min at 13,000 rpm. The supernatant containing total
protein was immunoprecipitated using α-Flag, α-HA beads overnight. The beads with
bound protein were washed and the protein was eluted with 100 mM glycine (pH 2.2) and
quickly neutralized with 150 mM tris (pH 8.8). The eluted protein was subjected to SDSPAGE on 4-15% gel (Bio-Rad, Hercules, CA) and visualized with Gel Code Blue. A
coomassie gel with HA-iNOS is shown in Figure 4-1.
iNOS-C-tail (1041-1153 amino acids) retaining the PDZ-motif was cloned into
pET-41- and pTriEx-4 vectors to generate GST-His-S-iNOS-C-tail and His-S-iNOS-Ctail, respectively. The idea of generating this construct was increased options of affinity
tags, ease of purification with a smaller construct and performing biochemical assays.
GST stands for Glutathione-S-Transferase protein (26 KDa) which is a commonly used
epitope tag for protein purification and exhibits high affinity for glutathione agarose
Proteins were induced in an E.coli bacterial system using IPTG and retrieved after
bacterial lysis using suitable lysis buffers as described in Chapter 3 Methods. The GSTfusion and His-tagged proteins were purified using affinity chromatography involving
glutathione beads and talon beads, respectively. Talon beads are precharged with Co2+
with a unique tetradentate metal chelator and exhibit high specificity for His-tagged
proteins. For the GST-tagged protein elution was done using 10 mM glutathione in PBS
(pH 7.4). His-S-iNOS-C-tail protein was eluted in 200 mM Imidazole prepared in
resuspension buffer (described in Chapter 3 Methods). Glutathione and imidazole act
competitive to GST and Histidine residues binding to the respective resins facilitating the
elution of the proteins. The eluted proteins were further purified using size exclusion
chromatography. Purified GST-His-S-iNOS-C-tail and His-S-iNOS-C-tail are shown in
Figures 4-2A and 4-2B respectively, on a coomassie stained gel. The protein smear
appearing below the major band in Figure 4-2B represents partial degradation of the
protein.
Alternatively, fluorescent CFP-tagged iNOS and Yellow (a variant of YFP)tagged NHERF2 constructs were obtained or cloned to perform protein-protein
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Figure 4-1.

Purification of HA-iNOS

Coomassie stained gel showing purified full-length HA-iNOS (~ 130 KDa) from HAiNOS overexpressing HEK-293 cells.
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Figure 4-2.

Purification of truncated iNOS proteins

Coomassie stained gel showing purified (A) His-S-iNOS-C-tail and (B) GST-His-SiNOS-C-tail (1041-1153 amino acids) expressed in E.coli.
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interaction studies in live cells using FRET. Yellow tag was preferred over YFP because
of its improved spectral properties and better signal. HEK-293 cells were the ideal choice
to perform protein-protein interaction studies and make stable cell lines because they
originate from human, are easy to transfect, and respond to various agonists.
iNOS Exhibits High Affinity Interaction with NHERF2
Given that iNOS harbors a putative PDZ motif to bind to PDZ-domain containing
scaffolding proteins, we first screened the interaction of iNOS with different PDZ
proteins to identify the high-affinity interactions of iNOS. An array of GST-tagged PDZ
proteins (NHERF1, NHERF2, and PDZK1) referred to as a PDZ array was generated. A
PDZ array comprises of proteins immobilized on nitrocellulose membrane using a slot
blot applicator. It allows screening of preferential protein-protein interactions and the
relative binding affinities of various PDZ-proteins towards a specific protein at the same
time. In the mentioned experiment, the immobilized PDZ-proteins were screened for
binding to GST-His-S-iNOS-C-tail (100 ng) in buffer comprised of 0.1% Tween-20 and
2% BSA in PBS in an overnight binding at 4°C. Our results demonstrated that NHERF2
showed the highest binding affinity towards iNOS, whereas NHERF1 showed a weak
binding and PDZK1 did not bind to iNOS (Figure 4-3A). A similar assay is referred to as
a dot-blot assay where protein samples are dropped on to a nitrocellulose membrane in a
volume of 1-2 µl using a pipette on a self-drawn grid and allowed to dry. His-tagged
protein His-S-MAST205 was used as a positive control for the assay. The second
interacting protein GST-His-S-iNOS-C-tail (100 ng) is added to the membrane in 3-5 ml
of 0.1% Tween-20 and 2% BSA in PBS and binding is performed overnight at 4°C. Next
day the membrane is washed six times with 0.1% Tween-20 in TBS and probed with SHRP antibody (1:5000) at room temperature for 1 h. The membrane is again washed
extensively with 0.1% Tween-20 in TBS six times for five min each. The membrane is
developed with ECL™ chemiluminescence solution. The data is shown in Figure 4-3B.
Given the fact that iNOS is not normally expressed under native conditions, HEK293 cells were transiently transfected with full-length pcDNA3-iNOS (1 µg) using
Lipofectamine 2000. Cells are subsequently lysed in 0.2% Triton-X-100 buffer in PBS.
The rationale behind using Triton-X-100 based lysis buffer is that Triton-X-100 is a nonionic detergent which does not interfere with protein-protein interactions, After the lysis,
lysate enriched in proteins is subjected to a pull-down assay with GST-NHERF2. The
rationale of this experiment is to elucidate interaction of NHERF2 with full-length iNOS.
In this assay, GST-NHERF2 (0-15 µg) is allowed to mix with the HEK-293 iNOS
overexpressing cell lysate for 1 h. GST-NHERF2 interacting protein complexes are then
immobilized on glutathione beads overnight. Next day, beads are washed to remove
unbound and non-specific proteins and the protein complexes are eluted in 5X laemmli
buffer containing 5% β-mercaptoethanol, subjected to SDS-PAGE and western blot. The
blot was probed with a mouse monoclonal against iNOS. A concentration-dependent
interaction was observed between iNOS and GST-NHERF2 (Figure 4-4). Coimmunoprecipitation and immunoblotting were also used to detect the interaction
between full-length iNOS and NHERF2 in an overexpression condition. These
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Figure 4-3.

iNOS preferentially binds NHERF2 among NHERF proteins

An immunoblot showing GST-tagged PDZ proteins immobilized on nitrocellulose
membrane in (A) a slot-blot (B) dot-blot format probed with S-HRP for detecting
interaction with His-S-iNOS-C-tail.
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Figure 4-4.

NHERF2 immunoprecipitates full-length iNOS from the cells

An immunoblot for full-length iNOS, overexpressed in HEK-293 cells
immunoprecipitated with GST-NHERF2.
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procedures are based on the principle of immunoprecipitation which in coimmunoprecipitation principally involves capturing native interactions in the cells using
antibodies conjugated to resins. We generated a stable HA-iNOS (and Flag-iNOS)
overexpressing HEK-293 cell line using a lentiviral expression based system and the full
length purified protein is shown in Figure 4-1. Certain protein-protein interactions can be
quite transient and unstable and can disappear in stressful lysis and wash steps. For
transient interactions, proteins can be covalently cross-linked using a cross-linker, which
would help prevent loss of binding partners. NHERF2 interaction with iNOS could not be
detected as such and required cross-linker. We used DSP for cross-linking the proteins. A
temperature condition of 37°C and preciseness of time is very critical for successful
cross-linking. DSP (10mM) was added to the cells in pre-warmed PBS with Ca2+ (100
µM) and Mg2+ (1 mM) and incubated for 10 min at 37°C followed by lysis in cold PBS
0.2% Triton-X-100 buffer. HA beads (100 µl) were added to immunoprecipitate the
complex. The next day, samples were eluted using glycine buffer and western blot was
performed and probed with rabbit polyclonal NHERF2 antibody. We detected that
NHERF2 co-immunoprecipitated with iNOS upon cross-linking the complex (Figure
4-5).
Next, using direct sensitized FRET, we investigated whether the interaction could
be detected in live cells. FRET is a procedure to detect protein-protein interactions in live
cells involving a radiationless mode of energy transfer from one chromophore referred to
as donor to second chromophore referred to as acceptor that exists within a diameter of
100 nm of the donor. HEK-293 cells were co-transfected with CFP-iNOS (donor) and
Yellow-NHERF2 (acceptor) to measure normalized corrected FRET value (N-FRETc).
The FRET is being mentioned as corrected as the bleed-through values deriving from
acceptor excitation in the absence of donor with the donor excitation wavelength have
been accounted for in the final measurement. Using the FRET module of SlideBook 4.2
software, an approximate FRETc value of 35 ± 4% N- was estimated at the plasma
membrane in cells that co-expressed CFP-iNOS and Yellow-NHERF2 (Figure 4-6A).
The control group comprised of HEK-293 cells co-expressing CFP-iNOS donor with
Yellow-fluorophore acceptor. Little or no FRET signal was observed in the controls
(Figure 4-6B).
The specificity of PDZ-dependent iNOS-NHERF2 interaction was further
investigated using a highly sensitive amplified luminescent proximity homogenous assay
(AlphaScreenTM). The assay is referred as homogenous as no washing steps are involved
in the process. Also, AlphaScreenTM can detect very low affinity interactions in the
picomolar range. The fundamental requirement of an AlphaScreenTM readout is the
proximity of excited donor and acceptor beads within 200 nm. Donor and acceptor beads
are conjugated with affinity molecules that can be matched with the epitopes on target
proteins. Donor beads contain a photosensitizer, phthalocyanine, which when excited at
680 nm generates an excited and a reactive form of O2, singlet oxygen. Singlet oxygen
would transfer energy to thioxene derivatives within the acceptor bead if present in the
right proximity of the donor bead leading to an emission of 520-620 nm wavelength
which is quantified as counts per second (cps) in a microplate reader. The usual readout
of a pair-wise protein-protein interaction with AlphaScreenTM is in the form of a bell-
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Figure 4-5.

iNOS and NHERF2 exist within a protein complex in the cells

Western-blot data to depict co-immunoprecipitated NHERF2 and HA-iNOS in HEK-293
cells using a cross-linker DSP and probed with rabbit NHERF2 polyclonal antibody.
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Figure 4-6.
in the cells

iNOS and NHERF2 protein complex exists at the plasma membrane

(A) Representative pseudocolor images showing the expression of CFP-iNOS and
Yellow-NHERF2 in HEK-293 cells. The intensity of direct sensitized FRET (N-FRETc)
between CFP-iNOS and Yellow-NHERF2 at the plasma membrane was shown in a
monochrome mode, according to a temperature-based look-up table (n=3 independent
experiments). (B) Representative pseudocolor images showing the expression of CFPiNOS and Yellow-fluorophore in HEK-293 cells. N-FRETc in the co-transfected cells
was shown in pseudocolor and monochrome modes.
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shaped curve termed as Hook-effect. Hook-effect is the common read-out profile of
saturable bimolecular detection systems including FRET and AlphaScreenTM. Standard
curves obtained with AlphaScreenTM are characterized by a titratable increase in signal
until it attains a maximal value termed as hook point. After the hook point signal begins
to drop as excessive concentrations of target molecules oversaturates the donor and the
acceptor beads and restricts their association. The interaction between GST-NHERF2
(100 nM) and GST-His-S-iNOS-C-tail (30 nM to 300 µM) or Biotin-iNOS-C-tail peptide
(last 10 amino acids; QPSSLEMSAL; 30 nM to 300 µM) was studied using
AlphaScreenTM. GST (100 nM) was used as a control in these experiments. A micromolar
range interaction was observed for GST-His-S-iNOS-C-tail and biotin-iNOS peptide with
GST-NHERF2, while no interaction was observed in the GST control (Figures 4-7A and
4-7B). The specificity of the interaction was demonstrated by the competition-based
assay between biotin-iNOS and iNOS peptides for interaction with GST-NHERF2. The
interaction between GST-NHERF2 and biotin-iNOS peptide was disrupted in a
concentration-dependent manner by the untagged iNOS peptide, while DMSO did not
disrupt the interaction (Figure 4-8).
Taken together, our data demonstrate that iNOS exhibits a high-affinity
interaction with NHERF2. PDZ proteins have been shown to mediate the localization of
various proteins at or near the plasma membrane, thereby enabling cell polarization to
mediate vectorial functions (120). Given that, NHERF2 binds to PDZ-domain proteins
predominantly associating with the plasma membrane and there is high amount of FRET
signals between iNOS and NHERF2 at the plasma membrane, we reasoned that iNOSNHERF2 interaction may play an important role in mediating apical localization of iNOS
and in coupling it with other apical membrane-bound proteins. Towards this end HEK293 cells with a knockdown of NHERF2 were generated and about 50% knockdown was
achieved with these cells compared to HEK-293 cells with scrambled siRNA (Figure
4-9). These cells were immunostained for overexpressed iNOS to demonstrate the role of
NHERF2 in regulating sub-cellular localization of iNOS. HEK-293 cells with scrambled
siRNA exhibited higher sub-apical membrane localization compared to NHERF2
knockdown cells (Figure 4-10). In order to demonstrate the relevance to colon epithelial
cells, human colon epithelial cell line HT29-CL19A were transfected with iNOS and
iNOS-∆PDZ, with the latter lacking the ability to bind NHERF2 (Figure 4-11). First,
HEK-293 cells were transfected with iNOS and iNOS-∆PDZ and lysed, and a pull-down
was performed with GST-NHERF2 immobilized on glutathione beads in a similar
manner as described above. Interaction of iNOS with GST-NHERF2 served as positive
control for the experiment. Based on this data, HT-29CL19A cells were immunostained
for iNOS and it could be demonstrated that removal of PDZ-motif reduced sub-apical
localization of iNOS (Figure 4-12). This data implies that iNOS-NHERF2 interaction has
pathological relevance.
NHERF2 Bridges CFTR and iNOS into a Macromolecular Signaling Complex
Given that (i) iNOS binds with high affinity to NHERF2 and localizes primarily
at the membrane (108); and CFTR interacts with NHERF2 with high affinity (42), we
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Figure 4-7. GST-NHERF2 and iNOS protein fragments interaction using
AlphaScreen™ assay
AlphaScreen™ assay to determine the binding affinity between (A) biotin-iNOS-C-tail
peptide and GST-NHERF2 and (B) His-S-iNOS-C-tail and GST-NHERF2 (n=3
samples).
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Figure 4-8.
peptide

AlphaScreen™ competition assay for GST-NHERF2 and iNOS-C-tail

AlphaScreen™ competition assay shows that a non-biotinylated iNOS peptide competes
against biotin iNOS peptide for binding to GST-NHERF2 protein, verifying the
specificity of the interaction (n=3 samples).
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Figure 4-9.

NHERF2 knockdown in HEK-293 cells

Western blot to demonstrate NHERF2 knockdown in HEK-293 cells using lentiviral
siRNA particles. Bar-graph to quantitate around 50% knockdown of NHERF2 compared
to scrambled siRNA. β-actin was used for protein normalization.
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Figure 4-10. Role of NHERF2 in determining iNOS localization inside the cell
iNOS immunostaining in HEK-293 cells with no iNOS expression and without NHERF2
knockdown (upper panel), with iNOS expression and without NHERF2 knockdown
(middle panel) and with iNOS expression and NHERF2 knockdown (bottom panel).
HEK-293 cells with no NHERF2 knockdown represent cells transduced with scrambled
siRNA.
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Figure 4-11. PDZ-interaction based iNOS-NHERF2 coupling
Western blot depicting pull-down of full-length iNOS and iNOS-∆PDZ with GSTNHERF2. Removal of PDZ motif disabled interaction of iNOS with NHERF2.
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Figure 4-12. PDZ-interaction dependence of iNOS localization in colon epithelial
cells
iNOS immunostaining in HT-29CL19A cells with no iNOS expression (left panel), with
iNOS expression (middle panel) and with iNOS-∆PDZ expression (right panel).
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rationalized that a macromolecular complex might exist among CFTR, NHERF2, and
iNOS with NHERF2 serving as the scaffolding protein. Abilities of NHERF proteins to
assemble macromolecular complexes of CFTR of functional relevance have been shown
previously and described in detail in Chapter 2. A plausible explanation of NHERFs as
preferred scaffolds for CFTR is their predominant sub-apical localizations in polarized
epithelial cells (120). Also, NHERFs can anchor enzymatic and regulatory proteins and
therefore act as conduits of regulatory influences on CFTR channel activity (22, 30, 34,
121). It is to be noted that NHERF scaffolds are not limited to CFTR and have been
shown to assemble many signal-transduction complexes at the plasma membrane which
immensely profile vectorial physiology (122). Nonetheless, NHERF mediated complexes
of CFTR have been shown to be central to fluid regulation and its ability to function as
conductance regulator. To test whether a complex of CFTR-NHERF2-iNOS exists, we
performed an in vitro macromolecular formation assay with purified GST-His-S-iNOS Ctail, GST-NHERF2, and Flag-CFTR proteins. Briefly, His-S-iNOS C-tail (20 µg) and
GST-NHERF2 at two different concentrations (5 and 15 µg) are mixed first for 1 h and
immobilized on S-beads (20 µl). Purified Flag-CFTR is then added to the protein-bead
mix and allowed to interact overnight at 4°C. An assembled protein complex
immobilized on S-beads is shown in Figure 4-13 (upper panel). A macromolecular
complex of CFTR and iNOS could be inferred from the data shown in Figure 4-13
(lower panel).We found that the complex could only be assembled when NHERF2 was
present, and that the formation of this complex increased in a NHERF2-dependent
manner Figure 4-13 (lower panel). It correlates with the fact that stoichiometry of CFTR
and NHERF scaffold determines the efficiency of CFTR macromolecular assemblies.We
proceeded to determine NHERF2 mediated CFTR-iNOS interaction using PLA in HEK293 cells. Briefly, iNOS and Flag-CFTR were overexpressed in HEK-293 cells with and
without NHERF2 knockdown. The knockdown process did not impair the ability of the
cells to overexpress proteins and equal levels of iNOS and Flag-CFTR proteins were
detected in scrambled and NHERF2 knockdown cells. NHERF2 knockdown reduced the
amounts of PLA signals in iNOS and Flag-CFTR co-transfected cells by 50% (Figure
4-14). As mentioned and demonstrated before that tempering with the CFTR and
NHERF2 stoichiometry affects CFTR macromolecular assemblies and plausibly control
the dynamics of interaction. We used direct sensitized FRET to test if iNOS and CFTR
interaction can be altered by controlling the concentration of NHERF2 in live cells.
Toward this end, HEK-293 cells were co-transfected with CFP-iNOS and YFP-CFTR
and subjected to FRET imaging. N-FRETc signal between CFP-iNOS and YFP-CFTR at
the plasma membrane was very weak but could be visualized on a small temperaturebased FRET look up scale (Figure 4-15A). Increasing the expression of NHERF2 by
transfecting the cells with different amounts of pCMV-HA-NHERF2 cDNA (0, 0.2, 0.5,
0.75 and 1 µg), enhanced the N-FRETc signals by 2- to 2.5-fold compared to the HANHERF2 untransfected cells (Figure 4-15B). Only selective data is presented here to
emphasize the concept. Concomitantly, with the presence of greater amounts of
NHERF2, there will be more iNOS getting trafficked to the plasma membrane and the
possibility of achieving macromolecular associations with CFTR would be higher.
Transfection with more than 1 µg of HA-NHERF2 could not further increase the FRET
signal, implying that the complex was already saturated.
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Figure 4-13. CFTR-NHERF2-iNOS macromolecular complex
A pictorial representation of the macromolecular complex assay (upper panel). A
macromolecular complex (MMC) was detected in vitro with three purified proteins (HisS-iNOS-C-tail, GST-NHERF2, and Flag-CFTR) (lower panel).
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Figure 4-14. Knockdown of NHERF2 expression compromises CFTR-iNOS
physical coupling at the plasma membrane
Representative images of the PLA assay in HEK-293 cells with scrambled and NHERF2
knockdown transfected with pcDNA3-empty vector (left, indicated by symbol φ), FlagCFTR and iNOS both (middle and right). PLA signal was quantified as fluorescence
intensity and represented in the form of a bar-graph (lower panel). Data represent the
mean ± SEM (n=8-49 regions of interest); *****P < 0.00001 as determined using
student’s t-test.
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Figure 4-15. Modulating iNOS-CFTR interaction at the plasma membrane
(A) Representative direct sensitized FRET depicting interaction between CFTR and
iNOS at the plasma membrane in HEK-293 cells. The cells were single or cotransfected
with CFP-iNOS and YFP-CFTR, and the pseudocolor images show the expression. HANHERF2 was also included in the transfection media to increase N-FRETc. N-FRETc
between CFP-iNOS and YFP-CFTR at the plasma membrane was shown in a
monochrome mode, according to a temperature-based look-up table.
(B) Bar graph represents the increase in N-FRETc between CFTR and iNOS with
increasing concentrations of HA-NHERF2. Data represent the mean ± SEM (n=3
independent experiments, 8-10 regions of interest per experiment); ****P < 0.00001 as
determined using student’s t-test.
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iNOS Protein Is Organized into Clusters at or near the Apical Plasma Membrane in
Inflammatory Bowel Disorders
iNOS levels have been shown to be upregulated in colonic biopsies from IBD
patients in UC and CD, and enhanced NOS levels and associated disease manifestations
are better correlated in UC patients than in Crohn’s colitis patients (75). Inflammation
patterns in UC vs. CD appear superficially similar but are distinct. Inflammation in CD
can be found in any part of the gastrointestinal tract and usually occurs in the forms of
patches and extends beyond the mucosa into deeper layers of the gut. In UC,
inflammation extends proximally from the rectum and is restricted to the colon, usually
occurs in a continuum and affects the mucosal surface only (99). Due to better correlation
between iNOS function and pattern of inflammation in UC, the current study focuses on
UC. Costello et al. (2005) used human endoscopic biopsies from sigmoid colons of
normal individuals and patients suffering from active CD and UC to examine the pattern
of genome-wide gene expression in IBD (123). The sample size comprised a total of 31
individuals with the data from normal (n=11), CD (n = 10) and UC patients (n = 10) to be
included for the analysis. The transcripts were datamined corresponding to iNOS,
NHERF2, and CFTR in active UC-affected biopsies and were compared with those in the
normal control samples. The rationale behind including CFTR in the analysis is based on
three facts. First, IBD patients have severe diarrhea and CFTR function is directly
correlated with the development of diarrhea. Whether CFTR contributes to diarrhea in
IBD is not known. Second, we have demonstrated that iNOS binds NHERF2 and
previously, several studies have described interactions between CFTR and NHERF
proteins. Therefore, it becomes reasonable to explore the possibility of iNOS and CFTR
being connected to NHERF2. Third, iNOS can be functionally coupled to CFTR chloride
channel function as iNOS can stimulate cGMP production via the canonical NO-cGMP
pathway and it is already known that cGMP can potentiate CFTR activity. We
determined that iNOS expression level was 2-fold higher in UC patients compared to the
normal controls (Figure 4-16). The change in CFTR expression levels was not
significantly altered, and NHERF2 expression slightly increased in UC patients compared
to the normal individuals (Figure 4-16). This correlates with the prevailing data on iNOS
activity in IBD-affected patients which is increased by 2-3 fold and also, with the
determined expression changes in CFTR in IBD which have been not quite consistent.
Change in expression of NHERF2 in IBD-affected tissue has not been determined
previously and our current analysis demonstrates that NHERF2 levels are not
significantly altered in IBD.
Histological staining of normal and UC-affected human colon tissues showed
disrupted mucosal architecture and massive infiltration by the immune cells (Figure
4-17). Using immunohistochemical analysis, we confirmed the increase in iNOS levels
and its predominant localization at or near the apical plasma membrane in UC-affected
colon compared to normal colon (marked arrows in upper panel; Figure 4-18). NHERF2
was found to localize predominantly at or near the apical plasma membrane in both
normal and UC colons (marked arrows in middle panel; Figure 4-18) and the expression
of CFTR protein was unchanged in UC-affected colon compared to the normal ( marked
arrows in lower panel; Figure 4-18). In order to quantitate the relative changes in protein
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Figure 4-16. iNOS, CFTR and NHERF2 expression profiles in UC-affected human
colon tissue
Normalized intensities of mRNA expression of iNOS, CFTR, and NHERF2 from human
mRNA expression data sets in colonic biopsies from normal and active IBD-suffering
individuals. Data represent the mean ± SEM (n=10-11 per group).
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Figure 4-17. H&E stained normal and UC-affected human colon tissue sections
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Figure 4-18. Immunostaining for iNOS, CFTR and NHERF2 expression in normal
and UC-affected human colon sections
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expression of iNOS, CFTR and NHERF2 ImageJ was used and mean gray values were
obtained as depicted in the form of bar-graphs in Figures 4-19A through 4-19C.
In order to demonstrate that there are high amounts of iNOS associated with the
plasma membrane in IBD, Total internal reflection microscopy (TIRFM) was performed
on the normal and UC-affected tissue present close to the coverslip. TIRFM can visualize
single molecule fluorescence with high resolution to capture events taking place at or
near the plasma membrane within a span of 200 nm (124). The thickness of plasma
membrane is approximately 8 Å. TIRFM is based on the generation of an evanescent
wave at the water-glass interface as a result of the phenomenon of total internal reflection.
The evanescent electromagnetic field decays exponentially from the interface and can
penetrate up to 200 nm into the sample medium and therefore, falls within the range of
visualizing basal plasma membrane. UC-affected and -unaffected tissues were stained
with primary mouse monoclonal iNOS antibody followed by anti-mouse Alexa-fluor-488
secondary antibody. Antibody stained slides were excited at 488 nm and imaged using
the TIRF module of the microscope. Using TIRFM, we could identify iNOS clusters at
the plasma membrane in UC biopsies suggestive of its involvement in spatially restricted
signaling complexes at the plasma membrane (marked arrows; Figure 4-20). The data
also points to the direction that in IBD epithelial cell membranes are enriched with iNOS;
therefore, at these membranes the iNOS-NO-sGC-cGMP pathway will be predominantly
operative.
In order to validate our in vitro data on the pathophysiological existence of iNOSNHERF2 interaction, an IBD simulating animal model of chemically-induced colitis
involving oral administration of DSS was developed. Specifically the model was tested in
C57BL/6 Nherf2+/+ vs. Nherf2-/- mice and the immunoblot shows the absence of
NHERF2 in Nherf2-/- mice (Figure 4-21A). Kidney tissue was included for the western
blot analysis as NHERF proteins are highly abundant in the kidney. Please note that the
DSS-colitis model closely relates to UC conditions and the associated iNOS-upregulation
and is also the most appropriate model to study UC (75). DSS administered in the water
for 7 days induces severe acute colitis in mice. Colon tissues from different groups were
excised and processed for histological staining. The microscopic sections of the DSSchallenged colons from the Nherf2+/+ and Nherf2-/- mice groups showed a range of
histopathological features characteristic of DSS-induced colitis, including mucosal edema,
epithelial cell and crypt damage, and immune cell infiltrates characterizing an
inflammatory colon (Figure 4-21B). Histological scores were also quantified and no
significant differences were observed between Nherf2+/+ and Nherf2-/- mice (Figure
4-21B). iNOS-specific immunostaining confirmed similar upregulation of iNOS in
response to DSS treatment in both Nherf2+/+ and Nherf2-/- mice compared to untreated
mice (Figure 4-22). Also, DSS-challenged mouse colons had upregulated iNOS levels at
the apical plasma membrane of the gut epithelia (marked arrows; Figure 4-22). Therefore,
the absence of NHERF2 does not affect the expression of iNOS under colitis. Therefore,
consequences of depleted NHERF2 will be on iNOS trafficking to the plasma membrane
as demonstrated in Figures 4-10 and 4-12. Moreover, it will also lead to reduced iNOS
involvement in highly localized signaling at specialized plasma membrane microdomains.
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Figure 4-19. Quantitated iNOS, CFTR and NHERF2 expression in normal and
UC-affected human colon sections
Bar-graphs represent quantification of (A) iNOS, (B) CFTR and (C) NHERF2
expressions as mean gray values in normal and UC-affected human colon sections. Data
represent the mean ± SEM; ****P < 0.001, ns= non-significant determined using
student’s t-test.
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Figure 4-20. iNOS clusters at the plasma membrane in UC-affected human colon
epithelia
TIRF images of normal and UC-affected human colon tissues immunostained for iNOS
depicting organization of iNOS into clusters in UC-affected human colon tissue (marked
arrows).
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Figure 4-21. DSS-colitis in Nherf2+/+ and Nherf2-/- mice
(A) Immunoblot for NHERF2 expression in Nherf2+/+ and Nherf2-/- mouse kidney and
colon lysates. (B) H&E stained untreated (upper panel) and DSS-treated (lower panel)
Nherf2+/+ (left panel) and Nherf2-/- (right panel) mouse colon sections. Bar graph
represents the histology score of the colon sections from DSS-treated Nherf2+/+ and
Nherf2-/- mice. Data represent the mean ± SEM (n=3-5); ns= non-significant.
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Figure 4-22. iNOS expression in DSS-colitis
iNOS specific immunostained DSS-treated and untreated Nherf2+/+ and Nherf2-/- mouse
colon sections. Numbers 1-4 indicate the representative images of the four groups of
mouse. Bar graph represents the quantitation of the iNOS expression in the sections from
DSS-treated and untreated Nherf2+/+ and Nherf2-/- mice. Data represent the mean ± SEM
(n=4 regions of interest); *P < 0.05, **P < 0.01 determined using student’s t-test.
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Interaction of iNOS and NHERF2 in UC-affected human colon tissue was
qualitatively determined using proximity ligation assay (PLA). The interaction between
two proteins appears as red PLA signal if the specific antibodies binding to the proteins
are proximal to each other within a span of 40 Å and many previous studies have
validated the application of the assay in determining protein complexes and colocalizations in vivo (125, 126). The advantage of this assay is the ability to determine
protein-protein interactions in tissues rather than limiting to a cell system and also, the
assay can be used with the fixed tissues and cells unlike FRET-based assays.
Fundamental approach of the PLA assay is labeling the cells or tissue with the antibodies
specific to proteins of interest, followed by addition of species specific probes conjugated
with oligonucleotides. If the proteins are present and interacting in the right proximity
required for successful PLA, there will be a polymerization reaction of the conjugated
nucleotides, incorporating fluorescent nucleotides and generating a signal termed as the
PLA signal. We observed significant amount of PLA signals at the plasma membrane of
the colon epithelial cells in UC-affected tissues signifying the interaction between iNOS
and NHERF2 (lower panel, marked arrows; Figure 4-23) while almost no PLA signal
was observed in normal human colon tissues (upper panel; Figure 4-23).
In order to demonstrate the physiological existence of a CFTR-NHERF2-iNOS
macromolecular complex in the DSS-induced colitis model, colon mucosal epithelial
cells scraped from the control and DSS-treated animals were used and CFTR and iNOS
were probed for in the immunoprecipitated complex with purified GST-NHERF2
immobilized on glutathione beads. CFTR could be detected in a complex with GSTNHERF2 in both control and DSS-treated colon mucosal epithelial cells while iNOS was
detected in the complex in DSS-treated tissue only (Figure 4-24). To ensure the
physiological existence of a CFTR-NHERF2-iNOS macromolecular association, coimmunoprecipitation was performed in DSS-treated Nherf2+/+ mouse colon with iNOS
specific antibody and CFTR and NHERF2 were detected in the complex with iNOS
(Figure 4-25). Thus, with the evidence of induced expression of iNOS at the apical
plasma membrane possibly due to its interaction with NHERF2 in IBD, there is a high
probability of involvement of iNOS in contributing to altered vectorial physiology in the
IBD gut.
iNOS Potentially Constitutes cGMP Microdomains
Because we previously observed that iNOS is overexpressed at the apical plasma
membrane in gut epithelial cells, we tested whether iNOS contributes to cGMP
production at the plasma membrane. To this end, ratiometric FRET was performed to
monitor cGMP dynamics in HEK-293 cells expressing a membrane-bound cGMP sensor,
m-Cygnet 2.1. Ratiometric FRET is a FRET-based procedure customized to monitor the
changes in the levels of small molecules such as Ca2+, cAMP and cGMP based on the
specific sensitivities towards these molecules of unimolecular FRET-based sensors which
comprise of a donor and acceptor fluorophore in the same molecule (127-129). cGMPspecific sensors termed as Cygnets are very sensitive to cGMP levels in the nanomolar
range and allow detection of spatial associations of cGMP production inside the cell
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Figure 4-23. iNOS-NHERF2 interaction in UC-affected human colon tissue
PLA in human colon tissue sections depicting interaction between iNOS and NHERF2 in
UC-affected human colon tissue sections appearing as a red signal termed the PLA signal
(marked arrows).
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Figure 4-24. Pull-down of CFTR and iNOS using purified GST-NHERF2 in DSStreated colon mucosa
Western blot data depicting pull-down of proteins from colon mucosa tissue lysate from
DSS-treated and untreated mice with purified GST-NHERF2 (20 µg) and probed for
CFTR (left) and iNOS (right).
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Figure 4-25. Immunoprecipitation of CFTR-NHERF2-iNOS macromolecular
complex in DSS-treated colon tissue
Western blot data depicting colon tissue lysate from DSS-treated mice coimmunoprecipitated with anti-iNOS antibody and probed for CFTR and NHERF2.
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(130). Increase in the cGMP is monitored by calculating the ratio of CFP/FRET which
has been designed to increase upon binding of cGMP to the sensor. The membrane-bound
sensor was generated by inserting the myristoylation-palmitoylation site into the Nterminus of cygnet 2.1 backbone sequence which anchors the protein in the plasma
membrane (Figure 4-26). Using this sensor we can specifically monitor cGMP dynamics
at the plasma membrane. There was an increase in cGMP levels at the plasma membrane
(equivalent to increase in CFP/FRET ratio) upon adding the cGMP-elevating agent,
zaprinast, and cells that overexpressed iNOS showed a higher baseline and zaprinastinduced CFP/FRET ratio (i.e., level of cGMP is high) at the plasma membrane (Figure
4-27), all of which suggested that iNOS contributes to cGMP generation at the plasma
membrane. Although, it is understood that NO is quite a diffusible molecule however, the
predominant association of iNOS at the plasma membrane as clusters in UC colon
epithelia corroborates the idea of enrichment of the membrane with localized NO
signaling. The evidence of increased cGMP in the presence of iNOS at the plasma
membrane suggests close proximity of iNOS and soluble guanylate cyclase and the
feasibility of localized generation of cGMP at the membrane. Therefore, it can be
concluded that compartmental NO-cGMPsignaling may exist at the plasma membrane.
It is understood that iNOS-governed microdomains would involve an active NOcGMP pathway with the sGC present in the proximity. Since cGMP is a known activator
of CFTR chloride channel function, we tested the impact of iNOS overexpression on
CFTR function. Towards this end, cGMP modulators, zaprinast and sildenafil, which are
phosphodiesterase-5 inhibitors (PDE5-inh; PDE5 is a cGMP-specific diesterase) were
used in various cell culture studies. An added explanation to the use of PDE5-inh is the
close communication and colocalization of NOS-sGC machinery with PDE5 as
demonstrated previously in cardiac myocytes (131, 132). We detected significant
amounts of PDE5 in HEK-293 and HT29-CL19A cells and epithelial cells from pig colon
(Figure 4-28). It was mostly detected as a cytosolic protein with small amounts of the
protein associated with the membrane fraction (Figure 4-28; left).
iNOS Physical Interaction with CFTR Forms the Basis of CFTR Channel Activity
Potentiation
CFTR is localized primarily at the apical plasma membrane of gut epithelial cells
and can be found enriched in the isolated membranes of pig colon epithelial cells as
shown in Figure 4-29 (34). In view of apical localization of iNOS and its involvement in
cGMP production at the apical plasma membrane, it is likely that iNOS functionally
couples with CFTR and augments CFTR function at the plasma membrane via the NOcGMP pathway. CFTR-mediated halide influx was determined in HEK-293 cells with
(here referred to as HEK-293-N) or without (here referred to as HEK-293-S) NHERF2
knockdown and overexpressing Flag-CFTR, iNOS and a YFP-based halide sensor,
pCDNA3-TM-Cl-. CFTR mediated I- influx was monitored in response to extracellular
addition of zaprinast (250 µM) in 136 mM NaI which activated CFTR function and lead
to decreased intracellular YFP fluorescence (133). CFTR-dependent halide flux in
response to zaprinast reduced by 28% in the cells having the partially compromised
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Figure 4-26. Generation of m-cygnet 2.1
Schematics of how membrane-bound cGMP sensor m-cygnet 2.1 was generated.
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Figure 4-27. iNOS potentially constitutes cGMP microdomains at the plasma
membrane
Representative pseudocolor images of CFP/FRET emission ratio before (time=0) and
after adding 250 µM zaprinast (time =10 min) in HEK-293 cells, transiently expressing
membrane-bound cGMP sensor m-Cygnet 2.1, and transfected with pCDNA3 empty
vector (upper panel) and pcDNA3-iNOS (lower panel). Representative line graph to show
CFP/FRET emission ratio change over time upon adding the agonist. Bar graph
represents baseline and zaprinast-induced CFP/FRET emission ratio in empty vector vs.
iNOS-transfected HEK293 cells. All data are mean ± SEM (n=3); *P < 0.05 as
determined using student’s t-test.
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Figure 4-28. PDE5 expression in various cell systems
Western blot data to show PDE5 expression in post-nuclear supernatant (PNS), cytosol
(CYT) and membrane (MEM) fractions of the pig distal colon tissue lysate (left) and, in
HEK-293 and HT29-CL19A total cell lysate (right).
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Figure 4-29. CFTR expression in colon mucosal epithelial cells
Western blot data to show CFTR expression in post-nuclear supernatant (PNS), cytosol
(CYT) and membrane (MEM) fractions of the pig distal colon tissue lysate.
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macromolecular complex of CFTR and iNOS due to NHERF2 knockdown compared to
that in the cells with intact NHERF2 (Figure 4-30A). CFTR function was not
significantly different in HEK-293-S-Flag-CFTR and HEK-293-N-Flag-CFTR (Figure
4-30B).
iNOS Potentiates CFTR Chloride Channel Function in a Cell Inflammatory Model
PDE5-inh-dependent stimulation of CFTR currents has been demonstrated in lung
airway cells (6). Viagra, a derivative of PDE5-inh, is used for treating male impotence,
and, interestingly, patients who take the drug have diarrhea as a side-effect (134). We
demonstrated that zaprinast increases CFTR-dependent short-circuit currents (8) in
HT29-CL19A cells in a dose dependent manner (Figure 4-31A). We also measured
iodide efflux rate in HT29-CL19A cells, and, consistent with the Isc measurement,
zaprinast augmented CFTR function in the treated cells (Figure 4-31B). Forskolin a
global activator of AC and CFTR chloride channel function was used as a positive
control. It was observed that the effect seen with zaprinast on CFTR-function was small
which may be accounted by the nature of how most of the PDEs function i.e. in a highly
compartmentalized fashion. Therefore, high concentration of zaprinast was used for the
studies. The nature of how PDEs usually function in cells has been reviewed in Chapter 1.
In order to elucidate the possibility of CFTR and iNOS physical and functional coupling
at the plasma membrane, polarized HT-29CL19A cells were immunostained for CFTR
and iNOS. HT29-CL19A cells endogenously express CFTR and iNOS was exogenously
overexpressed in these cells. Immunofluorescence stained polarized cells demonstrated a
high abundance of CFTR and iNOS at the apical plasma membrane and these two
proteins are partially co-localized (Figure 4-32). Colon mucosal epithelial cells are
known to be the major contributors of intestinal inflammation in IBD, so we investigated
CFTR function in vitro in HT29-CL19A cells in response to an inflammatory challenge.
These colon epithelial cells reportedly showed induced iNOS mRNA and increased
nitrite levels in response to various cytokines (135). We simulated inflammatory
conditions in HT29-CL19A cells by subjecting the cells to a cytokine mix or cytomix for
48 h. The rationale of inducing inflammation in order to study outcomes of iNOS upregulation on CFTR function is to present a more relevant physiological model
representative of in vivo inflammatory conditions. Subsequently, the relative change in
iNOS-specific mRNA levels was determined using real-time PCR. iNOS expression
increased almost 6-fold in response to the cytokines compared to the untreated controls
(Figure 4-33). A small increase in the expression levels of CFTR and NHERF2 was also
observed (Figure 4-33). We monitored Isc and measured iodide efflux rate in HT29CL19A cells pretreated with or without cytomix. After establishing basal currents or
basal iodide secretion, cells were incubated with an inducer of iNOS, L- arginine (1 mM),
for 15 min. CFTR was then activated with 250-400 µM zaprinast. CFTR Cl- channel
function increased by 1.5- to 2-fold in cytomix-treated cells compared to the untreated
cells (Figure 4-34). The difference of the effect on CFTR function observed between
cytomix-treated and untreated sample was not dramatic which might be possible due to
highly compartmentalized activation of CFTR within iNOS microdomains and it can be
speculated that additional factors might be required in vivo in order to observe massive
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Figure 4-30. Knockdown of NHERF2 expression compromises CFTR-iNOS
functional coupling
(A) Averaged representative traces of CFTR-mediated I- influx in HEK-293-S (scrambled
siRNA) and HEK-293-N (NHERF2 siRNA) cells overexpressing Flag-CFTR and iNOS
in response to 250 µM zaprinast. PAR refers to the cells with no Flag-CFTR and iNOS.
Quantification of the data represented as change in YFP fluorescence (n = 6). (B)
Averaged representative traces of CFTR-mediated I- influx in HEK-293-S (scrambled
siRNA) and HEK-293-N (NHERF2 siRNA) overexpressing Flag-CFTR in response to
250 µM zaprinast (n=4-6). Data are mean ± SEM; **P < 0.01 as determined using
student’s t-test.
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Figure 4-31. Zaprinast induced CFTR-chloride channel function
(A) Representative traces of CFTR-mediated short circuit currents (Isc) currents in
polarized HT29-CL19A cells treated with various concentrations of zaprinast. CFTRinh172 was added to the apical side at the end of the experiment. (B) Line graph represents
CFTR-mediated iodide efflux rate in HT29-CL19A cells activated with forskolin (50 µM)
or zaprinast (250 µM).
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Figure 4-32. Localization of CFTR and iNOS in polarized HT29-CL19A cells
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Figure 4-33. iNOS, CFTR and NHERF2 expression in cytomix challenged colon
epithelial cells
The bar graph represents the fold change in iNOS, CFTR, NHERF2 transcripts by using
real-time PCR (TaqMan probe-based method) in HT29-CL19A cells treated with cytomix
for 48 h. Data represent the mean ± SEM (n=3).
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Figure 4-34. CFTR chloride channel function in cytomix-treated colon epithelial
cells
(A) Representative trace of CFTR-mediated short circuit currents (Isc) in polarized HT29CL19A cells treated with cytomix for 48 h vs. untreated. Bar graph represents the
maximal increase in Isc (cytomix treated vs. untreated cells) (n=3). (B) Bar-graph to show
the maximal increase in iodide efflux rate to monitor CFTR activity in cytomix-treated
vs. untreated HT29-CL19A cells (n=6). Data are mean ± SEM; *P < 0.05, **P < 0.01 as
determined using student’s t-test.
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activation of CFTR chloride channel function. Also, an inflamed colon would present
massive and highly active iNOS to regulate CFTR function which is challenging to
achieve in a cell culture model.
Based on the abovementioned findings, it can be concluded that tight association
of iNOS with the apical plasma membrane in IBD and polarized colon epithelial cells
would form the basis of iNOS-dependent stimulation of CFTR in a highly
compartmentalized fashion at the plasma membrane.
Inhibition of CFTR and iNOS Activity Attenuates Diarrhea in DSS-induced Colitis
No convincing data exists on the role of CFTR in IBD-associated diarrhea and
many in vivo animal and human studies have emphasized that anion secretion may not be
altered in colitis (103). With the major role of CFTR in regulation of fluid regulation
across intestinal epithelial and pathogenesis of secretory diarrhea, it is considerably
important to conclusively determine the role of CFTR in the pathogenesis of diarrhea in
IBD (136). Ma et al. developed a highly specific thiozolidinone CFTR-inhibitor
(CFTRinh-172) which could significantly attenuate CTX-induced diarrhea in mice when
administered intraperitoneally (150 µg/kg for 6 h) or orogavaged (250 µg/kg for 6 h) in
these mice (137). More than 90% reduction in the CTX-induced fluid secretion could be
observed in mice orogavaged with the inhibitor. Based on these observations and highly
specific action of CFTRinh-172 on CFTR, in order to conclusively determine if CFTR has
a contribution in UC-associated diarrhea, colitis was developed in C57BL/6 mice using
5% DSS in the presence and absence of intraperitoneal administration of CFTRinh-172
(150 µg/kg) 5-day post DSS treatment. Preference was given to IP administration than
orogavaging as the latter may have an effect on drinking water uptake by the mice.
Control animals for the experiment included mice intraperitoneally administered with or
without CFTRinh-172 (150 µg/kg) and normal autoclaved drinking water. Mice treated
with DSS develop diarrhea and suffer from weight loss (117). The experimental layout of
the experiment is represented and changes in the body weights of all the mice in each
group were monitored every day in the span of the experiment (Figure 4-35).
Administration of CFTR inhibitor was based on the appearance of symptoms in DSStreated animals. Animals started showing symptoms on the 4th day of DSS-treatment.
Mice were sacrificed on the 8th day, and colons were removed for calculation of wet/dry
weight, relative colon length, bleeding score and histological examination. Mice
administered with CFTRinh-172 exhibited reduced weight loss (25%) and fluid secretion
compared to the untreated animals in the DSS group (Figures 4-35 and 4-36).
Administration of CFTRinh-172 improved colitis conditions which included, less-reduced
colon length, rectal bleeding score, wet/dry weight ratio compared to sole DSS treatment
(Figure 4-37). In the absence of CFTRinh-172, the wet/dry weight of colon was higher by
35% vs. when present (Figure 4-37). Interestingly, the histology score was not
significantly altered with the inhibitor compared to the DSS-alone treatment (Figure
4-38). To the best our knowledge, this is the first study which sought to evaluate the role
of CFTR in DSS-induced colitis and our data demonstrated that CFTR contributes
significantly to DSS-induced diarrhea which can be extended to IBD-associated diarrhea.

79

Figure 4-35. Inhibition of CFTR function causes partial protection against weight
loss in DSS-colitis
A layout of the experiment involving CFTRinh-172 treatment in DSS colitis model. Line
graph shows the mouse total body weight measurements over a period of 7 days of the
four-mice group; saline ± DSS treatment and CFTRinh-172 ± DSS. No DSS treatment
groups had 3 mice each. DSS treatment group comprised of 5-8 mice. Bar-graph to show
the total change in body weight of the mice on day 7 in DSS± CFTRinh-172 experimental
group. Data are mean ± SEM; *P < 0.05 as determined using student’s t-test.
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Figure 4-36. Inhibition of CFTR function attenuates fluid secretion in DSS-colitis
Representative separated mouse colons of the various treatment groups. Upper panel
shows colon of the mice with no DSS ± CFTRinh-172. Lower panel represents the colon
isolated from mice in the DSS ± CFTRinh-172 treatment experimental group.

81

Figure 4-37. Inhibition of CFTR function causes partial protection in DSS-colitis
Bar-graphs show the assessments of various disease parameters of the DSS-induced
colitis including bleeding and stool score and wet to dry weight ratio of the fecal pellets
in the mice not receiving or receiving intraperitoneal injection of CFTRinh-172. X-Y
scatter plot depicts the colon lengths of the mice in various groups. Control groups had 3
mice each. DSS treatment group comprised of 7-8 mice per group for CFTRinh-172
treatment. Data are mean ± SEM; *P < 0.05 as determined using student’s t-test.
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Figure 4-38. Histological scores are unaltered in the presence of CFTR inhibitor in
DSS-colitis
H&E stained colon sections of the mice from DSS ± CFTRinh-172 treatment experimental
group Bar graph represents the histology score of the colon sections. Data represent the
mean ± SEM (n=6-12); ns= non-significant as determined using student’s t-test.
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These observations have important clinical implications that CFTR inhibitors can have
beneficial effects in the therapeutic intervention of IBD.
In order to elucidate the role of iNOS in DSS-induced diarrhea and colitis, we
investigated the consequences of inhibiting iNOS activity in vivo in DSS-treated mice on
fluid secretion in the colon. Previous studies have consistently determined that loss of
iNOS causes reduced severity of DSS-induced colitis (138). Ablation of iNOS in TNBScolitis has generated equivocal results (75). However, it was concluded that the acute
phase of colitis is critically affected by iNOS presence and activity in TNBS colitis and
the absence of iNOS increases susceptibility to mucosal injury (111, 139). Based on these
studies it can be understood that iNOS can have varied contribution in even closely
related forms of inflammation. Therefore, generalization of an iNOS-dependent
phenomenon must be precariously applied to other related gastrointestinal inflammatory
disorders. Whether there exists an organ-specific phenotype of CFTR-iNOS
macromolecular association in other organ-related inflammatory conditions needs to be
further studied and evaluated.Studies involving use of NOS inhibitors have also
generated mixed information and the inconsistencies largely stemmed from the narrow
window of selectivity and specificity towards iNOS of these inhibitors and it has been
inferred that certain NOS activity from nNOS might be essential for keeping the gut
healthy (75, 112). Exogenous NO-donors could stimulate electrolyte secretion in guinea
pig mucosa with the role of endogenous NO largely undetermined (140).
A recently published study documented the curative effects of iNOS inhibition
using L-NIL on smoke induced pulmonary emphysema where it could prevent the
development when co-administered with the smoke threat and could also reverse
deterioration associated with the established emphysema (141). Other studies have
reported specific action of L-NIL in the resolution of several other inflammatory profiles
and in modulating inflammatory phenotypes in different models of intestinal
inflammation. Considering the therapeutic effects of L-NIL on resolution of an
inflammatory profile, we tested the effects of iNOS in DSS-colitis murine model and also,
determined how endogenous NO generated from iNOS can alter fluid secretion in colon.
L-NIL was administered intraperitoneally in a temporal variation in DSS-challenged
wild-type mice. The temporal component of iNOS treatment is critical in view of
suggested correlation between stage of iNOS inhibition and its outcome on disease
activity index in experimental colitis models as mentioned previously (75). Fluid
secretion was attenuated in L-NIL treated mice colons compared to the untreated (Figure
4-39). Animals treated with L-NIL one day after DSS-treatment appeared healthier and
had significantly smaller weight loss (16.3%) compared to the mice receiving
intraperitoneal saline administration (Figure 4-39). Interestingly, mice which were
treated with L-NIL three and five days after DSS-treatment trended to show improvement
in the body weights compared to the control, however, it was less significant compared to
the animals treated with L-NIL one day after colitis induction. No difference was
observed in the animals which were administered with L-NIL or saline without DSS in
the drinking water. Also, the disease activity parameters were significantly improved
upon L-NIL treatment compared to the controls (Figure 4-40) which indicates the
curative effects of L-NIL on DSS-induced colitis. The histological scores were improved
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Figure 4-39. Inhibition of iNOS function causes partial protection against weight
loss and attenuates fluid secretion in DSS-colitis
A layout of the experiment involving L-NIL treatment in DSS colitis model. Bar-graph to
show the maximal change in body weight of the mice on day 7 in DSS± L-NIL
experimental group. DSS treatment group comprised of 4-5 mice per group. The right
panel represents the colon isolated from mice in the DSS ± L-NIL treatment group.
Arrows are marked to show the extent of fluid secretion in the colon. Data are mean ±
SEM; **P < 0.01 as determined using student’s t-test.
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Figure 4-40. Inhibition of iNOS function causes partial protection against DSScolitis
The bar-graphs show the assessments of various disease parameters of the DSS-induced
colitis including bleeding and stool score and wet to dry weight ratio of the fecal matter
in the mice not receiving or receiving intraperitoneal injection of L-NIL. X-Y scatter plot
depicts the colon lengths of the mice in various groups. Control groups had 3 mice each.
The DSS treatment group comprised of 4-5 mice per group for L-NIL treatment. Data are
mean ± SEM; *P < 0.05 as determined using student’s t-test.
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with L-NIL treatment (Figure 4-41) Levels of NO in the homogenized colon tissue were
quantified as nitrite using Griess reagent and normalized with the total protein
concentration. DSS-exposed colon tissues were enriched with high amounts of NO
compared to the unexposed tissue (Figure 4-42). The amount of NO was substantially
reduced in the L-NIL treated animal group. cGMP levels were also determined using
ELISA-based method and were found to be elevated in DSS-treated mice and decreased
in response to L-NIL treatment (Figure 4-42). The data signifies that NO-cGMP pathway
is actively operating in the DSS-colitis and is driven by up-regulated levels of iNOS.
Also, effects observed with L-NIL treatment on DSS-colitis correctly correlate the
contribution of endogenous NO contributed by highly active iNOS to increased fluid
secretion in the affected mice .Also, it can be inferred that a right coordination of iNOS
inhibition and its effect on other disease features of IBD than diarrhea can be explored as
a potential therapeutic approach to control UC. Although, iNOS will be expressed by
inflammatory cells also but secretory phenotype will be largely a contribution of
epithelial cells.
Diarrhea Is Attenuated in Nherf2-/- Mice in DSS- and TNBS-induced Colitis
Individuals suffering from IBD show severe diarrhea and weight loss. Given that
potentiation of CFTR channel function happens in a compartmentalized manner through
NHERF2-mediated formation of the CFTR-iNOS complex, we investigated the
consequences of disrupting the compartmentalized response by uncoupling the proteininteractome as would be the case in Nherf2-/- mice. It is now being established that
several macromolecular signaling complexes can become pathophysiological (46).
Intuitively formation of macromolecular complexes is an evolutionary advantage for cell
survival with the rationale that it prevents the dramatic functional effects of a protein and
at the same time would contain the pathophysiological aspects of protein function. The
current study emphasizes the fact the CFTR becomes pathophysiological in certain
microdomains at the plasma membrane in IBD. In case of IBD, plasma membrane gets
enriched with such microdomains and therefore, would simulate mass activated CFTR.
The question arises how this mode of CFTR function regulation by iNOS in localized
domains would be different from freely diffusing iNOS? The definitive advantage of
compartmentalized regulation of CFTR is the selective and specific activation of CFTR
and this also allows a major proportion of iNOS function to be channeled to CFTR
regulation. Formation of a macromolecular complex also determines the nature of action
of iNOS in the gut mucosa which would be predominantly vectorial. Our in vitro data
established that the CFTR-NHERF2-iNOS macromolecular signaling complex increases
CFTR function and that may have pathophysiological relevance to diarrhea in IBD. Next,
we questioned what happens if the macromolecular complex is disrupted and if it can be
beneficial for IBD therapeutics. DSS-induced colitis is the most widely used model that
involves chemical-triggered manipulation of epithelial integrity/permeability and induces
very reproducible severe acute colitis characterized by bloody diarrhea, ulcerations and
granulocytes infiltrations (142). It is a particularly useful model to study the contribution
of innate immune mechanisms of colitis and it gives the flexibility of inducing acute,
chronic, or relapsing conditions of colitis with manipulations according to the
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Figure 4-41. Inhibition of iNOS function improves histological scores in DSS-colitis
H&E stained colon sections of the mice from DSS ± L-NIL treatment experimental group
Bar graph represents the histology score of the colon sections. Data represent the mean ±
SEM (n=5-7); **P < 0.01 as determined by student’s t-test.
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Figure 4-42. Inhibition of iNOS function affects NO-cGMP signaling in DSS-colitis
(A) Bar graph represents nitrite levels in colon tissues in response to DSS and
DSS+LNIL treatment (n=3 colon tissue samples). (B) Bar graph represents cGMP levels
in colon tissues in response to DSS and DSS+L-NIL treatment (n=3-4 colon tissue
samples). All data are mean ± SEM; ***P < 0.001 as determined using student’s t-test.
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experimental needs. TNBS-colitis is the most widely used haptenating agent to initiate a
CD-like intestinal inflammation in the colon and can recapitulate many of the events
proposed to initiate and sustain human Crohn’s disease (143).
We tested the differences in intestinal fluid secretion and weight loss, two
indicators for secretory diarrhea, between Nherf2-/- and Nherf2+/+ mice in DSS- and
TNBS-colitis models. Fluid secretion and the extent of diarrhea were assessed by
calculating wet to dry weight ratio (wet/dry weight). Mice were weighed on a regular
basis for 7 and 3 days in DSS- and TNBS-colitis models, respectively. Symptoms of
colitis (rectal bleeding, weight loss) were observed from the 4th day onwards after DSS
treatment in all DSS-treated mice irrespective of the genetic background and similar
bleeding score and reduction in colon length was observed on day 7 in Nherf2-/- and
Nherf2+/+ DSS-treated mice. No symptoms of colitis were observed in the untreated
animals. TNBS was administered intra-rectally in ethanol based solution and mice
demonstrated rapid weight loss on day 2 post-TNBS treatment characterizing the
development of TNBS-induced colitis in both Nherf2-/- and Nherf2+/+ mice. Weight loss
was assessed on the 7th day of DSS treatment for all mice groups, and DSS-treated
Nherf2-/- mice had significantly smaller maximal weight loss compared to DSS-treated
Nherf2+/+ mice (~40%; Figure 4-43). On the 7th day, colons were exteriorized, and
wet/dry weights were calculated. Gross examination of the colons suggested relatively
higher fluid secretion in Nherf2+/+ compared to Nherf2-/- mice in the DSS-treated groups,
while no major difference was observed in the DSS-untreated group of animals (Figure
4-44). DSS-treated Nherf2+/+ mouse colon sections had ~39% higher wet/dry weight
compared to Nherf2-/- mice, and the values in the untreated mouse groups were not
significantly different (Figure 4-45). Similar to DSS-effects, Nherf2-/- were resistant to
TNBS-induced colitis and demonstrated 65% lower maximal weight loss compared to
Nherf2+/+ mice (Figure 4-46). Nherf2-/- mice exhibited lower stool consistency score and
wet to dry weight ratio was estimated to be lower by 42% in Nherf2-/- than Nherf2+/+ mice
in TNBS-colitis set-up (Figures 4-47 and 4-48). Similar histology scores were observed
in Nherf2-/- and Nherf2+/+ mice in TNBS-colitis (Figure 4-49).These studies suggested
that mice lacking NHERF2 were protected against DSS- and TNBS-induced diarrhea,
and NHERF2 is required to mediate the functional coupling between CFTR and iNOS.
Mass-Spectrometry of Purified iNOS
The identity of the protein purified from Flag-iNOS expressing stable cell lines
that indeed it is full-length Flag-iNOS protein was confirmed with mass spectrometry and
also, there was a pool of data on the various proteins as potential interacting partners or
modulators of iNOS function. Five major bands in iNOS immunoprecipitation lane were
subjected to MS analysis as shown in Figure 4-50 and the results are shown in Tables
4-1 to 4-5. Information on the functions of immunoprecipitated proteins was obtained
from http://www.uniprot.org. The Mowse score was calculated to opt out randomized
interactions of low Mowse score and keep proteins with high Mowse score.
A Mowse score in peptide mass fingerprinting is a “similarity score” based on the
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Figure 4-43. Nherf2-/- mice are partially protected against weight loss in DSS-colitis
An experimental layout of DSS treatment in Nherf2+/+ and Nherf2-/- mice for a period of
7 days. Line graph shows the mouse total body weight measurements over a period of 7
days of the four-mice group; Nherf2+/+ ± DSS treatment and Nherf2-/- ± DSS treatment.
Each group had 3-4 animals. Data are mean ± SEM; **P < 0.01as determined using
student’s t-test.
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Figure 4-44. Nherf2-/- mice exhibit reduced fluid secretion than Nherf2+/+ mice in
DSS-colitis
Representative exteriorized mouse colons of the various treatment groups. Upper panel
and lower panel shows colon of Nherf2+/+ and Nherf2-/- mice with no DSS and with DSS,
respectively. Arrows are marked to show the extent of fluid secretion in the colon.
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Figure 4-45. Nherf2-/- mice are partially protected against diarrhea in DSS-colitis
Bar-graphs show the assessments of various disease parameters of the DSS-induced
colitis including bleeding and stool score and wet to dry weight ratio of the fecal pellets
in the Nherf2+/+ and Nherf2-/- mice. X-Y scatter plot depicts the colon lengths of the mice
in various groups. Control groups with no DSS had 3 mice each. DSS treatment group
comprised of 8-10 mice per group. Data are mean ± SEM *P < 0.05, **P < 0.01, ***P <
0.005, ns= non-significant as determined using student’s t-test.
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Figure 4-46. Nherf2-/- mice are partially protected against weight loss in TNBScolitis
Line graph shows the mouse total body weight measurements over a period of 3 days of
the four-mice group; Nherf2+/+ ± TNBS treatment and Nherf2-/- ± TNBS treatment.
TNBS group had 5-8 animals. Data are mean ± SEM; **P < 0.01 as determined using
student’s t-test.
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Figure 4-47. Nherf2-/- mice exhibit reduced fluid secretion than Nherf2+/+ mice in
TNBS-colitis as depicted in the exteriorized colon sections
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Figure 4-48. Nherf2-/- mice are protected against diarrhea in TNBS-colitis
Bar-graphs show the measured stool score and wet to dry weight ratio of the fecal matter
in the TNBS-treated Nherf2+/+ and Nherf2-/- mice. TNBS treatment group comprised of
8-10 mice per group. Data are mean ± SEM; *P < 0.05., **P < 0.01 as determined using
student’s t-test.
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Figure 4-49. Histological scores are not different in Nherf2-/- mice than Nherf2+/+
mice in TNBS-colitis
H&E stained colon sections of the TNBS treated Nherf2+/+ and Nherf2-/- mice. Bar graph
represents the histology score of the colon sections. Data represent the mean ± SEM
(n=5-10); ns= non-significant as determined using student’s t-test.
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Figure 4-50. Immunoprecipitation of full-length HA-iNOS for mass-spectrometric
analysis of bands 1-5 as marked
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Table 4-1.

Mass-spectrometric analysis of immunopurified iNOS (Band 1)

Protein
Nitric oxide synthase,
inducible NOS2
Serine/threonine-protein
kinase Chk1

Mowse score
12890

Function
NO-synthesis

80

Cell cycle, DNA damage, DNA
repair
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Table 4-2.

Mass-spectrometric analysis of immunopurified iNOS (Band 2)

Protein
Heat shock protein HSP
90-beta
Heat shock protein HSP
90-alpha
Arf-GAP with coiledcoil, ANK repeat and PH
domain-containing
protein 2
Putative heat shock
protein HSP 90-beta 2
Heat shock cognate 71
kDa protein
Putative heat shock
protein HSP 90-beta 4
Interleukin enhancerbinding factor 3
Heat shock 70 kDa
protein 6
Pantothenate kinase 4
Heat shock protein 75
kDa, mitochondrial
Endoplasmin

Mowse score
2728

Function
Chaperone

2122

Chaperone

818

GTPase-activating protein

725

Chaperone

626

Chaperone

415

Chaperone

367

Transcription

296

Chaperone

241
185

Co-A synthesis
Chaperone

158

A-kinase anchor protein
8-like

135

Chaperone, proper folding of Tolllike receptors, ER-associated
degradation
Helicase A binding protein

Protein arginine Nmethyltransferase 5
Golgi-specific brefeldin
A-resistance guanine

123

Protein methylation

121

E3 UFM1-protein ligase
1

115

78 kDa glucose-regulated
protein

107

Probable Xaa-Pro
aminopeptidase 3

99

Post-Golgi vesicle-mediated
transport and regulation of ArfGAP
Negative regulation of NF-kappaB
transcription factor activity and
possibly acts as tumor suppressor
Chaperone and is involved in the
activation of unfolded protein
response in response to glucose
starvation
Protein processing and proteolysis,
implicated in polycystic kidney
disorders
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Table 4-2.

Continued

Protein
Mannosyloligosaccharide
glucosidase
Catenin beta-1

Mowse score
87

Function
Protein N-linked glycosylation via
asparagine

80

Acyl-CoA
dehydrogenase family
member 11
Junction plakoglobin

78

Component of Wnt-pathway and
also implicated in multiple-organ
cancer
Fatty-acid metabolism

Serine/threonine-protein
kinase TBK1

73

Sulfhydryl oxidase 2

71

Carnitine Opalmitoyltransferase 1,
liver isoform
Melanoma-associated
antigen D1
Cullin-5

68

Adherens junction organization
and cell migration
Triggers I-kappaB kinase/NFkappaB cascade and regulator of
innate immune response
Disulfide bond formation and
synthesis of H2O2
Lipid metabolism

67

Ubiquitination and apoptosis

65

Pyridoxal-dependent
decarboxylase domaincontaining protein 20
Dermcidin
Ran-binding protein 9

65

Ubiquitination and response to
osmotic stress
Carboxylic acid metabolic process

Coiled-coil domaincontaining protein 8

60

75

65
61

Proteolytic and antimicrobial
Can act as an adapter protein to
couple membrane receptors to
intracellular signaling pathways,
also involved in microtubule
nucleation and axonal guidance.
Negative regulation of
phosphatase activity, implicated in
dwarfism
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Table 4-3.

Mass-spectrometric analysis of immunopurified iNOS (Band 3)

Protein
Calcium-binding
mitochondrial carrier
protein
Stress-inducedphosphoprotein 1
Insulin-like growth factor
2 mRNA-binding protein
3
Stress-70 protein,
mitochondrial
Dolichyldiphosphooligosaccharide
glycosyltransferase
subunit 1

Mowse score
330

Function
Malate-Aspartate shuttle,
gluconeogenesis

236

Assembly of molecular chaperones
HSC70 and HSP90 complex
Regulation of cytokine
biosynthesis

159
154

Chaperone; negatively regulates
apoptosis
Glycosyltransferase activity

76
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Table 4-4.

Mass-spectrometric analysis of immunopurified iNOS (Band 4)

Protein
E3 ubiquitin-protein
ligase
Serine/threonine-protein
kinase 38

Mowse score
787

Serine/threonine-protein
phosphatase 2A 55 kDa
regulatory subunit B
alpha isoform
Serine
palmitoyltransferase 1
Glutamate dehydrogenase
1 (GLUD1)

196

MAP kinase-activated
protein kinase 5

90

Nucleophosmin

83

Striatin-4

66

Nicotinamide
phosphoribosyltransferase
Vacuolar protein sortingassociated protein 4A

64

321

181

Function
Ubiquitination and negatively
regulates mTOR pathway
Negative regulator of MAP3K1/2
signaling involved in regulation of
NF-kappaB signaling
Binds oncogene TP53 which
contributes to transformation and
malignancy
Sphingolipid metabolism and
homeostasis
Oxidation of Glutamate; Defects in
GLUD1 are the cause of familial
hyperinsulinemic hypoglycemia
type 6
Tumor suppressor
serine/threonine-protein kinase
participating in mTOR signaling
Proto-oncogene and wide-substrate
chaperone
Scaffolding protein for
calmodulin. Also binds
phosphatase 2A
NAD biosynthesis pathway
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61

Membrane fission for endosomal
sorting
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Table 4-5.

Mass-spectrometric analysis of immunopurified iNOS (Band 5)

Protein
Calmodulin

Mowse score
797

Calmodulin-like protein 3

143

Selenoprotein H

77

104

Function
Calmodulin-Ca2+control activity of
a large number of enzymes
especially kinases and
phosphatases, ion channels and
other proteins
Similar to calmodulin; gets
induced by TGF-β1
Cell redox homeostasis

probability of matching N peaks by random chance. A protein sequence will be assigned
a high Mowse score, with the high frequency of matched peaks or when a peak is
exclusive.
The majority of the proteins immune-precipitated with iNOS were involved in
protein sorting, processing and folding. Several proteins, including 78 kDa glucoseregulated protein, are known to be the components of unfolded protein response (UPR)
implying that the pathway gets activated in an iNOS- dwelling system or generally in an
inflammatory profile. Also, several proteins were found to be involved in various
pathological conditions and few could link iNOS and IBD manifestations. For example,
catenin beta-1 has been linked to the development of colorectal cancer and another
protein E3 UFM1-protein ligase acts as a tumor suppressor and negatively regulates NFkappaB transcription factor activity, which acts canonical to iNOS-upregulation, PP2A
subunit B isoform B55-alpha can regulate dephosphorylation of the oncogene P53,
MAPKAP kinase 5 is a tumor suppressor gene of mTOR pathway and nucleophosmin is
proto-oncogenic. This is important, as it is already known that IBD patients are at a
higher risk of developing colorectal cancer.
Several other proteins e.g., GLUD1, 78 kDa glucose-regulated protein, were
related to glucose metabolism or sensing. A recent report mentions the association of
iNOS with low-order inflammatory states such as obesity-linked Type-2 diabetes (144).
A major proportion of the protein was directly related but not limited to iNOS-pathway
which include endoplasmin, serine/threonine-protein kinase TBK1, sulfhydryl oxidase 2,
dermcidin, interleukin enhancer-binding factor 3, serine/threonine-protein kinase 38,
insulin-like growth factor 2 mRNA-binding protein 3 to name a few.
Immunoprecipitation of calmodulin was interesting as iNOS is Ca2+ insensitive
and calmodulin-regulation independent. Although, it is known that iNOS binds to
calmodulin, with the abundance of iNOS within an inflammatory system it is possible
that iNOS acts as calmodulin scavenger and modulate several important calmodulinregulated pathways. These results might be valuable in designing studies that center
iNOS-dependent pathways in inflammatory disorders and explain many phenotypes
associated with these diseases.
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CHAPTER 5.

DISCUSSION

Pathophysiology of IBD-associated diarrhea is not clearly understood, and new
molecular targets for its amelioration need to be identified. Spatial restriction of multiple
proteins in the form of a macromolecular complex enables a tight and fine-tuned
regulation of protein function. The goal of this study was to uncover a macromolecular
interaction that is constituted and contributes to diarrhea in IBD and that may provide
opportunities for possible therapeutic interventions.
Pathological Roles of iNOS
NO is an important cell signaling molecule which acts as a mediator of several
physiological functions such as e.g. neurotransmission, smooth muscle relaxation, wound
repair and immunomodulation (68). However, the physiological benefits are limited to
NO being synthesized when required for a brief period lasting up to few minutes (145).
When there is chronic NO production, it becomes pathophysiological. There is a
prevailing notion that iNOS upregulation is a cytoprotective response to an inflammatory
challenge. However, as NO production by iNOS is sustained it becomes cytotoxic. iNOS
function is now being implicated in the pathogenesis of a number of neurodegenerative
disorders such as amyotrophic lateral sclerosis, Alzheimers and Parkinson diseases,
cardiovascular diseases such as atherosclerosis and lung disorders such as chronic
bronchitis, asthma and emphysema, and metabolic disorders such as obesity-linked
insulin resistance. Many aspects for a role of iNOS in maintenance of an inflammatory
profile have been shown. Also, pharmacological manipulations to inhibit iNOS function
and knockout of iNOS in experimental colitis models and emphysema models have been
shown to lead to resolution of inflammation (112, 141). Noticeably, the temporal
resolution of NO-mediated effects was critical to achieve consistency in these studies.
However, there have been conflicting reports on the role of NO in water and electrolyte
secretion in colitis (112).
Compartmentalized NO-cGMP Signaling
Very few studies have reported compartmentation of NO-cGMP signaling. We
demonstrated that iNOS forms clusters near the plasma membrane in UC-affected gut
epithelial cells. Dimerization of iNOS is a prerequisite for its function. It is quite possible
that the clusters are comprised of iNOS multimers representative of a functional state of
iNOS in UC-affected tissue. Previous data show that NOS activities can be regulated
through protein–protein interactions and lipid modifications by governing their specific
intracellular locations and also the downstream events will be dependent on the amounts
of NO synthesized (33). For example, sGC gets stimulated with the nanomolar amounts
of NO, while peroxynitrites start getting synthesized in the micromolar range (33). All
these factors will critically control the spatiotemporal regulation of the NO-cGMP
pathway. We demonstrated a high-affinity interaction of iNOS with the PDZ-scaffolding
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protein NHERF2. A consistent observation with PDZ proteins is their predominant
association with plasma membrane and their unique binding specificities contributing to
formation of distinct complexes (43). This organizational capacity of PDZ proteins has
also been instrumental in recruiting many cytosolic proteins to the membrane and
mediating vectorial functions (69, 70). It is highly unlikely that large multiprotein
signaling complexes assemble randomly. The protein expression and localization is
spatiotemporally coordinated, further aided by specific post-translational modifications
(146). Palmitoylation of NOS2 on Cys3 as well as interaction with the PDZ-proteins
CAP-70 or EBP50 is essential to mediate its apical targeting (69, 70, 147). Also, these
interactions resulted in increased NOS2 dimerization essential for enzyme function (69).
It is very likely that iNOS-NHERF2 interaction will determine the plasma membrane
localization of iNOS in IBD where it can be involved in vectorial physiology. The
pathophysiological relevance of iNOS-NHERF2 interaction at the apical plasma
membrane was demonstrated using PLA. This is a first demonstration of protein-protein
interaction in a human disease tissue where the sample comprises of the UC-affected and
unaffected areas of the same patient. It is quite possible if the interaction between iNOS
and NHERF2 is compromised the iNOS potency to exacerbate disease pathology would
decrease.
It is conceivable from the fact of CFTR expression levels being unaltered in UC
as demonstrated with heat analysis of mRNA expression in human biopsies and
immunohistochemistry in UC-affected biopsies, that CFTR hyperactivation as
hypothesized in UC is more a regulatory phenomenon than mere increase in the protein
expression level. We demonstrate that CFTR regulation in IBD happens in the form of
CFTR being functionally coupled to iNOS in restricted microdomains at the plasma
membrane. It also needs to be emphasized that proximity of a cGMP-generating system
(iNOS and GC) needs to be proximal to the cGMP-effector system (PKG and CFTR) for
a compartmentalized regulation which is demonstrated in the current study to be achieved
in the form of a macromolecular signaling complex.
Diarrhea in Inflammatory Bowel Disorders
Many surface proteins such as bacterial receptors and transporters, and
scaffolding proteins have been identified to increase IBD susceptibility. A list of the
selective IBD susceptibility genes is shown in Table 5-1. Identification of these
susceptibility factors partially explain the molecular phenotype of IBD and has
immensely contributed in dissecting out the mechanisms that lead to IBD. However, there
is a huge lack of information about the interplay of various factors that cause IBD which
makes it still challenging to be managed.
Diarrhea in IBD presents a big obstacle for its effective management. Diarrhea is
a consequence of dysfunctional homeostasis when pro-absorptive and anti-secretory
mechanisms fail to be compensated. Net Na+ absoprtion and Cl− secretion into the lumen
set the osmotic gradients for hydro flux. Thus, it is critical to understand how Na+
absorption and active Cl− secretion may get disturbed and imbalanced in IBD and cause
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Table 5-1.

IBD susceptibility genes

Gene
NOD2/CARD 15
NOD1/CARD 4
IL23R, TNFSF15,
STAT3, IL12B, CCR6
and JAK2
OCTN1/N2
MDR1
CFTR
DLG5
GPX1, GPX2
ATG16L1, IRGM

Implications
Intracellular bacterial
receptor
Intracellular bacterial
receptor
Interleukin and related genes

References
(148, 149)

Organic Cation Transporters
ABC-transporter
ABC-transporter
PDZ protein
Peroxidases
Autophagy

(152)
(153)
(105)
(154)
(151)
(155)
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(150)
(151)

diarrhea. Net Na+, Cl− and water absorption has been found to be reduced in UC patients
and in patients with active CD. Decreased Na+ absorption is deduced to be majorly a
consequence of down-regulated expression of Na+ transporters and their regulatory
proteins which include NHE1 and 3 (excluding NHE2), aldosterone responsive β and γsubunits of ENaC, Na+/K+-ATPase-α, and NHERF proteins (156, 157). Also, NHE1 &
3,β-ENaC, and NHERF1 & 2 were found to be similarly down-regulated in experimental
colitis models (157). Additionally, NO could dose-dependently inhibit NHE3 activity in
Caco-2 cells (158). NHE3 couples strongly with NHERF proteins that inhibit the channel
function through cellular messengers-cAMP, cGMP and calcium and NHERF2 has been
found to regulate plasma membrane levels of NHE3 (159, 160). However, the
involvement of NHE3-mediated Na+ absorption and its dysregulation in NO-pooled IBDaffected mucosa would still be debatable with the precarious consideration of the fact that
NHE3 is poorly expressed in the colonic mucosa (161) and therefore, will have minimal
contribution towards UC-associated diarrhea. Speaking of Cl- secretory mechanisms in
IBD, the Cl--HCO3- exchanger down-regulated in-adenoma (DRA) present on the apical
membrane has reduced mRNA and protein levels in UC (156). However, very little data
exist on supporting the contribution of active anion secretion in IBD-associated diarrhea.
Also, the proinflammatory cytokines which also have been shown to play important role
in diarrhea failed to consistently affect anion secretion (103, 156). However, it needs to
be understood that IBD is a complicated disorder with innumerable pathological events
taking place concurrently. Also, the process of fluid secretion across the mucosal
epithelia is highly synergistic. Therefore, it is hard to functionally dissect out individual
contributions to electrolyte abnormalities in a whole ensemble of transporters in the
affected tissue. CFTR is a dominant player of the fluid secretory pathway of the gut to
the extent that CF mice did not secrete fluid in response to cholera toxin and they suffer
from meconium ileus (90). Therefore, how CFTR behaves functionally in IBD is critical
to be elucidated. Alterations in the mRNA or protein levels of CFTR have not been
conclusively determined. We demonstrated a mechanism in which CFTR gets regulated
in an iNOS-governed cGMP microdomain which ultimately contributes to diarrhea in
IBD. We demonstrated the concept in vitro by inducing iNOS levels in response to
cytokine challenge (cytomix) in colon epithelial cells and stimulating CFTR Cl- channel
function in the presence of a cGMP-elevating agent. Further the colocalization studies in
polarized colon epithelial cells confirmed that proximity of CFTR to iNOS at the apical
plasma membrane is the molecular basis of iNOS-dependent potentiation of CFTR Clchannel function.
PDZ-scaffolds in the Spatiotemporal Regulation of CFTR
NHERF2 has been demonstrated to be acting as a GKAP for cGKII for the
cGMP-mediated regulation of NHE3 (30). Also, cGKII is known to be the isoform to
mediate cGMP-responsive activation of CFTR. It is quite possible that NHERF2 exhibits
dual role of assembling CFTR and iNOS at the plasma membrane as well as functioning
as GKAP in the complex to spatiotemporally regulate CFTR function. NHE3 inhibition
was specific to NHERF2-cGKII complex as NHERF1 could not compensate for the
effect. The likely reason for NHERF1 to not to be able to constitute CFTR-iNOS
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complex in IBD, although, NHERF1 is a common binding partner for both the proteins,
is because of its inability to function as GKAP and also may be due to the subtle
differences in their locations or squences (30). Therefore, it is conceivable that deficiency
of NHERF2 would impair CFTR-iNOS complex formation and ameliorate diarrhea in
colitis. Using DSS-induced colitis, we demonstrated in vivo that Nherf2-/- mice are
partially protected against diarrhea as indicated by reduced weight loss, intestinal fluid
secretion, and wet/dry weight in the Nherf2-/- mice. Also, the overall pathological features
of DSS colitis improved in Nherf2-/- mice as suggested by histological examination. This
observation may pertain to the partial failure of iNOS to be properly localized inside the
cell in the absence of NHERF2 so that the debilitating effects of iNOS function on
mucosal integrity are mitigated. The biological significance of NHERF proteins in
mediating highly compartmentalized regulation of CFTR was recently recapitulated in
various PDZ-protein knockout models (49). Despite the fact that NHERF proteins exhibit
high sequence homology, overlapping tissue expression and subcellular localizations and
are predicted to be redundant based on physiological normalcy of selective knockouts,
their deficiencies produced discrete phenotypes of CFTR function. Fsk-mediated
stimulation of CFTR-dependent bicarbonate secretion was highly reduced in Nherf1 -/and β2-AR agonist failed to stimulate CFTR function altogether (49). Nherf2 -/- mice
exhibited higher Fsk-stimulated CFTR bicarbonate secretion and the accounting
mechanism was found to be LPA- mediated inhibition of CFTR function which requires
NHERF2 scaffolding. Also, it was concluded that NHERF1 and NHERF2 can function
independently of one another. Ablation of PDZK1 had no effect on basal and Fskstimulated CFTR secretions. PDZK1 couples CFTR and MRP4 in a macromolecular
complex and MRP4 inhibition augments CFTR Cl- channel function. Based on this
observation, Pdzk1-/- mice should have increased CFTR function. However, it is
important to consider that MRP4 regulates CFTR function in a highly compartmentalized
manner. Therefore, CFTR potentiation in response to Fsk which causes massive CFTR
activation can easily mask compartmentalized activation of CFTR in the CFTR-PDZK1MRP4 complex and therefore, Fsk is not an ideal reagent to conclude for the loss of
compartmentalized-downregulation of CFTR function in Pdzk1-/- mice. Additionally, the
studies were performed in the duodenal tissue which expresses very small amounts of
MRP4.
CFTR within the NO-governed Compartments
We observe that if iNOS function is inhibited within the complex with the iNOSinhibitor (L-NIL) in DSS-induced colitis, diarrhea is attenuated. However, the effect
observed was small which might be due to the nature of the mechanism by which iNOS
activates CFTR, which is a highly compartmentalized signaling. Whether CFTR within
the complex is subject to NO-mediated S-nitrosylation, a common NO-mediated posttranslational modification of the protein targets, and be regulated by the process is a
matter of contemplation and further studies. The process of S-nitrosylation would involve
nitration of tyrosine residues, which is usually a molecular consequence of high
concentration of NO, a process that will accelerate CFTR degradation (162). However,
this does not reconcile with the augmentation of CFTR function and unaltered protein
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expression in IBD-affected vs. normal mucosal tissue. It is quite possible that the amount
of NO within the CFTR-iNOS micro-compartments is not sufficient to induce Snitrosylation as NO is quickly neutralized by sGC in close proximity. The physiological
concentrations of S-nitrosoglutathione (GSNO), the endogenous NO-donor and
bronchodilator, has been shown to increase expression, maturation, and function of both
the wild-type and the ∆F508 CFTR (162). Whether S-nitrosylation of CFTR is involved
in GSNO-mediated effects is still not established. However, the mechanisms have been
broadly elucidated to be cGMP-dependent and independent (163). This aspect of iNOS
mediated regulation of CFTR in IBD would be a matter for future investigation.
Dissolution of Protein-protein Complexes as a Potential Therapy for IBD
Given the fact that the molecular composition of CFTR-containing complexes has
been shown to significantly influence the secretory profile of the gut and that it can also
culminate in a pathological condition, modulating such macromolecular associations can
be a valuable therapeutic approach. Also, with the restriction of mechanism within the
complex, this approach can be highly specific. Administration of a cell permeable LPA2specific peptide could disrupt the CFTR-NHERF2-LPA2 structural and consequently,
functional integrity. Also, inclusion of a competing peptide for MRP4-CFTR interaction
attenuated MK571 (an MRP4 inhibitor) - induced potentiation of CFTR function (5). Our
lab recently identified a cell-permeable, small-molecule compound, CO-068, that
preferentially inhibits LPA2–NHERF2 interaction and augments CFTR activity in Calu-3
cells and CFTR-dependent fluid secretion from pig tracheal submucosal glands (164).
Also, recent studies in our lab and by others have demonstrated that the functional rescue
of ∆F508-CFTR depends upon the macromolecular associations of the mutated protein
and it is quite possible that several drugs known to correct mutant protein functional
deficiencies would involve modulation of protein-protein interactions of CFTR (165).
Recently, a NHERF1-mediated complex of chemokine receptor CXCR2 with PLC-β2 has
been shown to regulate neutrophil infiltration during inflammation (166). Also, addition
of CXCR2-specific peptide (containing the PDZ motif) was found to suppress
neutrophilic chemotaxis and transepithelial migration of potential therapeutic relevance
to inflammatory disorders such as colitis, chronic lung inflammation and atherosclerosis
(166). Therefore, in our opinion specific disruption of iNOS-NHERF2 interaction will
likely attenuate UC-associated diarrhea and improve one of the most common symptoms
of UC.
Although it is tempting to speculate that regulation of CFTR function through
iNOS-elicited cGMP signaling will be a general mechanism in other inflammatory
phenotypes such as lung inflammation and pancreatitis wherein all these proteins are
present, we think extra caution should be exercised for such generalization since these
phenotypes largely depend upon the organ type. However, given the many similarities
shared by UC and related inflammatory disorders of the gut such as Crohn’s disease and
diverticulitis, our findings will help understand the associated diarrheal phenotype.
In short, our findings will advance the understanding of mechanisms accounting for the
diarrheal manifestations in IBD and help identify new targets and approaches to control
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the disease. Our study also has important implications for targeting other forms of
gastrointestinal inflammation.
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